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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Det finns fyra klaffar i hjärtat som öppnas och stängs varje gång hjärtat slår. Klaffarna 
möjliggör att blod pumpas runt till lungorna där blodet syresätts och sedan pumpas 
vidare ut i kroppen för syresättning av våra organ. En kropp utan hjärtklaffarnas 
rörelseförmåga, och därmed utan syre, är inte kompatibelt med liv. Aortaklaffen, som är 
lokaliserad mellan hjärtats vänstra kammare och stora kroppspulsådern, är den 
hjärtklaff som oftast behöver bytas genom kirurgiskt aortaklaffbyte. Vid ett kirurgiskt 
aortaklaffbyte klipper man ut den sjuka klaffen och ersätter den med en så kallad 
hjärtklaffprotes. Ungefär 1500 patienter i Sverige och nästan 300 000 patienter i 
världen genomgår kirurgiskt aortaklaffbyte varje år.1 Den vanligaste indikationen för 
aortaklaffbyte är en förträngning i aortaklaffen, så kallad aortastenos, vilket är en 
sjukdom som ökar i förekomst med stigande ålder. Eftersom livslängden hela tiden ökar 
kan man förvänta sig att ännu fler patienter kommer vara i behov av aortaklaffbyte i 
framtiden.  
En hjärtklaffprotes är gjord av mekaniskt material eller biologisk vävnad från gris eller 
ko. En mekanisk klaffprotes har fördelen att den har en mycket lång hållbarhet, men 
nackdelen att man efter operation måste ta medicinen Waran så länge man lever. 
Waran är ett mycket potent blodförtunnande läkemedel som förhindrar att blodet 
koagulerar runt klaffen men som samtidigt för med sig en risk för blödning. Den 
biologiska klaffprotesen kräver ingen behandling med Waran, men har istället en 
begränsad hållbarhet. Det finns därför en risk, framför allt hos yngre personer, att man 
senare i livet behöver genomgå ytterligare en operation för att byta ut klaffprotesen 
igen. Så vilken klaff väljer man – den mekaniska med en livslång risk för blödningar eller 
den biologiska med en risk för att behöva genomgå ytterligare en hjärtoperation? 
Vanligtvis rekommenderar man en mekanisk klaffprotes till yngre och i övrigt friska 
patienter och en biologisk klaffprotes till äldre patienter med en begränsad 
kvarvarande livslängd. Men var går gränsen mellan ung och gammal? Det är en av 
frågorna vi försökt besvara i den här avhandlingen. Vi har även studerat hållbarheten 
samt sjuklighet och överlevnad efter aortaklaffbyte med olika typer av klaffproteser.  
I första studien jämförde vi överlevnad efter aortaklaffbyte med två olika typer av 
biologiska aortaklaffproteser. En av dessa klaffar är gjord av material från hjärtsäcken 
från kalv (Perimount) och en är gjord av klaffvävnad från gris (Mosaic). Resultatet 
visade ingen skillnad i långtidsöverlevnad mellan klaffarna. Mosaic-klaffen hade en 
högre andel av patienter där den implanterade klaffprotesen var för liten i förhållande 
till patientens kroppsstorlek men detta hade ingen påverkan på överlevnaden i vår 
studiepopulation.  
I andra studien studerade vi funktionen av Mosaic-klaffen både tidigt och sent efter 
operation. Resultatet visade en acceptabel funktion, men det var en betydande andel av 
  
patienterna som hade ett ökat tryck över klaffprotesen vilket kan tyda på en sämre 
funktion. Detta hade emellertid ingen påverkan på överlevnaden i vår studiepopulation. 
I tredje studien undersökte vi långtidsöverlevnaden efter aortaklaffbyte med en 
mekanisk jämfört med en biologisk klaffprotes hos patienter mellan 50 och 69 år. 
Resultatet visade att patienter som fick en mekanisk klaffprotes hade bättre överlevnad 
än de som fick en biologisk klaffprotes.  
I fjärde studien jämförde vi långtidsöverlevnaden efter aortaklaffbyte mellan patienter 
med måttlig njurfunktionsnedsättning och patienter med normal njurfunktion. 
Resultatet visade att patienter med måttlig njurfunktionsnedsättning hade 34% högre 
risk för död under uppföljningstiden.  
I femte studien jämförde vi förekomsten av infektion i klaffen efter aortaklaffbyte med 
en mekanisk eller biologisk klaffprotes. Resultatet visade att infektion i klaffen är 
relativt ovanligt men att patienter med biologiska klaffproteser oftare drabbades än 
patienter med mekaniska klaffproteser.  
I den sjätte studien gjorde vi en litteraturöversikt över studier som jämfört överlevnad 
efter aortaklaffbyte med en biologisk klaffprotes gjord av kalvvävnad med en 
klaffprotes gjord av grisvävnad. En sammanslagning av resultat från de granskade 
studierna, en så kallad meta-analys, visade ingen skillnad i överlevnad efter 
aortaklaffbyte med en klaffprotes gjord av kalvvävnad jämfört med en klaffprotes gjord 
av grisvävnad.  
Kunskap om överlevnad efter operation med olika aortaklaffproteser och hållbarheten 
av olika aortaklaffproteser är viktig för att välja rätt klaffprotes till rätt patient. Genom 
att undersöka detta leder avhandlingens studier till ökad kunskap om 
aortaklaffoperationer, om funktionen av olika typer av klaffproteser och om faktorer 
som kan leda till ökad sjuklighet och dödlighet efter operation. Denna kunskap är till 
nytta för patienter som har genomgått, eller som ska genomgå operation med 
aortaklaffbyte, både i Sverige och i andra delar av världen.
  
  
ABSTRACT 
Background Aortic valve replacement (AVR) can be performed with different types of valve prostheses. 
There is no perfect aortic valve prosthesis, and the prosthetic choice for each patient requires careful 
consideration. This thesis evaluates mortality, morbidity, and prosthetic valve function after AVR with different 
aortic valve prostheses.  
Methods and Results  
Study I We studied all-cause mortality and postoperative outcomes in all 1219 patients who underwent AVR at 
Karolinska University Hospital between 2002 and 2010 and received either Perimount (n=864; Edwards 
Lifesciences, Irvine, CA) or Mosaic (n=355; Medtronic, Inc., Minneapolis, MN) bioprostheses. There was no 
difference in all-cause mortality (adjusted hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.65–1.11) or 
rate of aortic valve reoperation between the two groups. Severe prosthesis–patient mismatch (PPM) was more 
common in the Mosaic group than in the Perimount group (15% vs. 6%, p<0.001).  
Study II We studied hemodynamic function and postoperative outcomes in all 355 patients who underwent 
AVR at Karolinska University Hospital between 2002 and 2008 and received a Mosaic bioprosthesis. The mean 
pressure gradient was 21.2 mmHg and 22.5 mmHg during early and late echocardiography, respectively. 
Moderate or severe PPM was found in 299 (84%) patients, and 46 patients had moderate or severe aortic stenosis 
at late echocardiography, but neither was associated with increased mortality. 
Study III We studied all-cause mortality and postoperative outcomes in all 4545 patients aged 50–69 years who 
underwent primary, isolated AVR with biological (n=1832) or mechanical (n=2713) prostheses in Sweden 
between 1997 and 2013. The study population was obtained from the SWEDEHEART register. In a propensity 
score-matched analysis, patients with mechanical valve prostheses had better survival than patients with 
bioprostheses (HR 1.34, 95% CI 1.09–1.66, p=0.006). There was no difference in the rate of stroke, but patients 
with mechanical valves had a higher risk of major bleeding events and a lower risk of aortic valve reoperation 
than patients with bioprostheses. 
Study IV We studied all-cause mortality and postoperative outcomes in all 13 102 patients with moderately 
reduced (n=3266), or normal (n=9836) kidney function who underwent primary AVR in Sweden between 1997 
and 2013. The study population was obtained from the SWEDEHEART register. Patients with normal kidney 
function had better survival than patients with moderately reduced kidney function (adjusted HR 1.28, 95% CI 
1.18–1.38). Patients with moderately reduced kidney function had a slightly higher risk of major bleeding events 
and a lower risk of aortic valve reoperation than patients with normal kidney function.  
Study V We studied the incidence of prosthetic valve endocarditis (PVE) in all 26 580 patients who underwent 
AVR with biological (n=16 426) or mechanical (n=10 154) prostheses in Sweden between 1995 and 2012. The 
study population was obtained from the SWEDEHEART register. The incidence rate of PVE was 0.57% (95% 
CI 0.54–0.61) per person-year. The incidence of PVE was highest during the first year after surgery and 
remained stable thereafter for up to 18 years of follow-up. The risk of PVE was higher in patients with 
bioprostheses than in patients with mechanical valve prostheses (adjusted HR 1.54, 95% CI 1.29–1.83, p<0.001).  
Study VI We performed a systematic review and meta-analysis evaluating all-cause mortality after AVR in 
49 190 patients who received bovine (n=32 235) versus porcine (n=16 955) bioprostheses. In total, seven articles 
met the inclusion criteria. The random-effects model was used to obtain pooled HR and 95% CI. The meta-
analysis revealed no difference in survival between the groups (pooled HR 1.00, 95% CI 0.92–1.09). 
Conclusions [1] Both the Perimount and Mosaic bioprostheses are acceptable valve alternatives for AVR. [2] 
In patients aged 50–69 years, survival after AVR was better for those who received mechanical valve prostheses 
rather than bioprostheses. [3] After AVR, patients with moderately reduced kidney function have higher 
mortality than patients with normal kidney function. [4] After AVR, the yearly rate of PVE was 0.57%. Patients 
with bioprostheses had a higher risk of PVE than that of patients with mechanical valves. [5] Both bovine and 
porcine bioprostheses are acceptable valve choices for AVR. 
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BMI Body mass index 
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INTRODUCTION 
Aortic valve replacement (AVR) is the standard treatment for patients with severe 
aortic valve disease. Surgical AVR is one of the most commonly performed cardiac 
procedures worldwide, and it is performed in approximately 280 000 patients 
worldwide each year.1 AVR is a procedure during which a diseased aortic valve is 
replaced with an aortic valve prosthesis. Operative mortality after isolated AVR is 
approximately 2%–3%.2,3 However, life expectancy after AVR is similar to that of the 
general population. 
Aortic valve prostheses are made of either biological tissue or mechanical material. 
Mechanical valves have excellent durability but necessitate lifelong anticoagulation 
treatment with warfarin, which requires a lifelong commitment to regular health care 
visits and increases the patient’s susceptibility to excessive bleeding. However, 
biological valves, or bioprostheses, do not require treatment with warfarin but have 
limited durability, which may necessitate reoperation. Bioprostheses are usually made 
from porcine heart valve tissue or bovine pericardial tissue. Several studies reported 
better hemodynamic function after AVR with bovine than porcine bioprostheses.4-6 
However, whether this translates to better survival for patients who receive a bovine 
than a porcine valve prosthesis is unknown.  
There are advantages and disadvantages to all types of aortic valve prostheses, and the 
prosthesis type has to be carefully selected for each patient.  
In this thesis, we studied the morbidity, mortality, and function of different types of 
valve prostheses after AVR. The overall aim was to increase the community’s level of 
knowledge about AVR and aortic valve prostheses. 
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BACKGROUND 
Aortic Stenosis 
Aortic stenosis is most commonly caused by calcification that narrows the opening of 
the aortic valve and subsequently obstructs blood flow. Aortic stenosis is responsible 
for a high number of hospitalizations and deaths every year. It is a common disorder, 
especially in the aging population, and it affects around 2% of the population aged 
above 65 years7 and up to 12% of the population aged above 75 years.8 
The aortic valve is composed of three cusps (therefore, it is also called the “tricuspid” 
valve), which are fused to the aortic root by three commissures. In younger patients 
with aortic stenosis, degenerative changes are often imposed on a congenital bicuspid 
valve (two cusps instead of the usual three). In contrast, older patients more commonly 
have acquired calcific changes in a tricuspid valve.9 Aortic valve disease can also be 
caused by a few less common conditions, such as endocarditis, rheumatic fever, aortic 
aneurysms, vasculitis, and Marfan’s syndrome.  
Patients with aortic stenosis have a wide array of clinical presentations, ranging from no 
symptoms to syncope and sudden death. The standard diagnostic tool for aortic valve 
disease is Doppler echocardiography. Valve structure, blood flow across the aortic valve, 
and the dimensions and function of the left ventricle are measured. Severe aortic 
stenosis is defined as a peak transvalvular velocity greater than 4 m/s, an aortic valve 
area less than 1 cm2, or a mean pressure gradient (MPG) across the valve greater than 
40 mmHg.10,11  
The prognosis of untreated aortic stenosis is poor, and the natural course of the disease 
is a progressive narrowing of the valve causing an increased cardiac workload, cardiac 
hypertrophy, cardiac failure, and eventually death. After the onset of symptoms, the 
annual mortality is 25%, and the average survival is 2–3 years.12 At present, no medical 
treatment cures or halts the progression of severe aortic valve stenosis, and the only 
curative treatment is AVR. 
Aortic Valve Surgery 
The first aortic valvuloplasty was performed in the 1920s with rather disappointing 
results.13 Not until after the first cardiac procedure with cardiopulmonary bypass in 
1953 did the first AVR take place in the early 1960s.13 In the beginning, caged ball 
prostheses were used, soon followed by homograft implantation. In the mid-1960s, a 
heterograft using porcine valve tissue was developed and implanted in a patient for the 
first time.13 The first stented bovine pericardial prosthesis was implanted in 1971. In 
1977, the first bileaflet mechanical valve was implanted, and that remains the most 
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commonly used type of mechanical valve prosthesis. The first transcatheter aortic valve 
implantation (TAVI) was performed in 2002 in France.14  
Surgical Aortic Valve Replacement 
Surgical AVR is one of the most commonly performed cardiac surgeries in the world, 
and approximately 280 000 AVRs are performed worldwide every year.1 The operation 
is recommended in symptomatic patients with severe aortic stenosis or regurgitation, 
and in asymptomatic patients with reduced left ventricular systolic function. It should 
be considered in case of severe aortic regurgitation with dilatation of the left 
ventricle.10,11 AVR is also performed in case of bacterial endocarditis or aortic dissection 
that affects the aortic valve.  
AVR is usually performed via full median sternotomy; however, in the last 2–3 decades, 
minimally invasive methods using a small chest wall incision have emerged as surgical 
options.15 Commonly used methods for minimally invasive AVR are upper 
hemisternotomy and right anterior thoracotomy. Studies have shown that a minimally 
invasive approach decreases postoperative pain, length of hospital stay, amount of 
blood transfusion, and incidence of postoperative atrial fibrillation, but at the expense 
of prolonged aortic cross-clamp time.16-18 Furthermore, less-invasive methods can only 
be used in selected patients.  
AVR is performed with cardiopulmonary bypass established with central venous and 
arterial cannulation before the proximal aorta is occluded with a cross-clamp. To 
prevent myocardial damage, cold blood or crystalloid cardioplegia is delivered through 
the coronary arteries or the sinus coronarius. The aortic valve is visualized through a 
partial aortotomy proximal to the aortic cross-clamp. The diseased valve is excised, and 
the aortic annulus is thoroughly decalcified before the aortic valve prosthesis is 
implanted. 
Operative mortality after isolated AVR is 2%–3%.2,3 In case of concomitant coronary 
artery bypass grafting or multiple valve intervention, operative mortality approximately 
doubles.2 The life expectancy of patients above 65 years of age after undergoing AVR is 
excellent and similar to that of the general population, and in patients below 65 years of 
age, it is approximately five years less than that of the general population.19  
The aortic valve can sometimes be repaired instead of replaced. Aortic valve repair is 
most commonly performed in patients with isolated aortic regurgitation, with the valve 
being modified by sutures and patches. This procedure allows the patient to keep his or 
her own valve, and excellent long-term results have been reported.20,21 However, aortic 
valve repair is usually more technically challenging than AVR, and it is reserved for 
selected patients.22 Aortic valve-sparing surgery with reimplantation of the aortic valve 
and the coronary arteries23 (i.e., David or Yacoub technique) into an aortic graft is 
another surgical technique that can be performed in selected patients. 
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Transcatheter Aortic Valve Implantation 
An alternative to open heart surgery for patients with symptomatic aortic valve disease 
is TAVI, a procedure in which an aortic valve prosthesis is implanted through a catheter, 
preferably via the femoral artery, but the possibility of using this access depends on the 
patient’s anatomy. The aortic prosthesis can also be delivered via the subclavian artery 
or transaortic or transapical approaches. The aortic valve prosthesis is implanted 
without removing the old, damaged valve. The entire procedure typically takes 1–2 
hours and can usually be performed with conscious sedation and local anesthesia rather 
than general anesthesia.  
Since the first TAVI procedure was performed in 2002, the method has rapidly gained 
ground. In 2016, it was estimated that TAVI had been performed in more than 200 000 
patients worldwide.24 The latest guidelines recommend TAVI in patients who have a life 
expectancy of more than one year and who are considered inoperable.10,25 In patients 
with high and intermediate surgical risk, TAVI is considered a reasonable alternative to 
surgical AVR.10,25 Randomized controlled trials (RCTs) investigating the use of TAVI in 
low-risk patients are ongoing. The choice of intervention (surgical AVR or TAVI) should 
be discussed by a multidisciplinary heart team after careful individual evaluation. TAVI 
carries a higher risk of postoperative need for pacemaker implantation, paravalvular 
leakage, and vascular complications than surgical AVR.26,27 However, TAVI has the 
advantage of a percutaneous approach allowing for a less invasive method with fewer 
postoperative bleeding complications and faster recovery. TAVI has also been 
associated with a lower risk of acute kidney injury and new-onset atrial fibrillation than 
surgical AVR.26,27 The 5-year durability after TAVI is similar to that of surgical AVR.28 
Further studies evaluating the long-term prognosis after TAVI are needed and ongoing. 
Complications after Aortic Valve Replacement 
Possible complications after AVR include bleeding, stroke, structural valve deterioration 
(SVD), infections including endocarditis and mediastinitis, thromboembolism, 
atrioventricular blocks requiring pacemaker implantation, and other arrhythmias such 
as atrial fibrillation.29 
Prosthesis-Patient Mismatch 
Prosthesis–patient mismatch (PPM) is present when the inserted prosthetic valve is too 
small in relation to the patient’s body surface area (BSA). The indexed effective orifice 
area is used to define PPM and is equal to the aortic valve area divided by the patient’s 
BSA. PPM and severe PPM are considered to be present when the indexed effective 
orifice area is less than 0.85 cm2/m2 and less than 0.65 cm2/m2, respectively.30  
PPM has been widely discussed over the last decades, and the evidence for its clinical 
impact is controversial. Several studies have shown a correlation between PPM and 
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reduced left ventricular mass regression, higher incidence of cardiac complications, and 
increased all-cause mortality.31,32 Other studies did not find that PPM is correlated with 
increased mortality.33,34 
Structural Valve Deterioration 
SVD is the deterioration of bioprostheses that typically takes place gradually over years. 
SVD is defined as leaflet calcification, tearing, thickening, or disruption of the prosthetic 
valve materials that manifest as aortic stenosis or regurgitation.35 Risk factors for SVD 
include young patient age, kidney failure, metabolic syndrome, hypertension, abnormal 
calcium metabolism, and PPM. The predicted 15-year risk of SVD is approximately 20% 
for patients 50 years of age, 30% for patients 40 years of age, and 50% for patients 20 
years of age.25 Surgical AVR or TAVI should be considered in symptomatic patients with 
SVD and severe aortic stenosis or regurgitation, or moderate stenosis and moderate 
regurgitation.35 
Prosthetic Valve Endocarditis 
Infective endocarditis is a rare but severe infection that can affect any surface with 
endocardial lining.36,37 It often affects heart valves,38 especially prosthetic ones. 
Prosthetic valve endocarditis (PVE) is the most severe form of infective 
endocarditis,39,40 and it accounts for 12% to 22% of all cases of infective 
endocarditis.40,41 The number of infections caused by staphylococci has increased over 
the last few decades to surpass streptococci as the most common pathogen in infective 
endocarditis in the Western world.41-43 This is believed to be caused partly by an 
increased number of nosocomial infections. Additionally, infective endocarditis now 
exhibits a more acute progression than in the past. It also more frequently affects older 
patients with prosthetic heart valves or cardiac devices, in contrast to earlier mainly 
affecting younger patients with rheumatic valve disease. PVE can result in valve 
dysfunction, embolic stroke, and sepsis. Without treatment, PVE is almost always fatal. 
Antibiotics should be started as soon as PVE is diagnosed, and surgery should be 
considered in all patients with PVE.44 Even with treatment, the reported in-hospital 
mortality rate of PVE is 15%–23%.40,45 The incidence of infective endocarditis in the 
general population ranges from 0.002% to 0.012% per person-year.46 However, the 
incidence of PVE after AVR has not been extensively studied, and whether PVE affects 
biological and mechanical aortic valve prostheses to the same extent remains unknown. 
Aortic Valve Prostheses 
The aortic valve can be replaced by either a biological or mechanical valve prosthesis. 
Mechanical prostheses have high long-term durability but necessitate lifelong 
anticoagulant therapy with warfarin, whereas biological prostheses do not require the 
use of anticoagulants but have limited durability. Bioprostheses typically last 10–20 
years but usually degenerate faster in younger patients.47,48 However, treatment with 
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warfarin requires a lifelong commitment to regular tests and an increased risk of 
bleeding-related complications. Additionally, in case of major bleeding or subsequent 
cardiac or non-cardiac surgery, anticoagulation therapy may have to be discontinued, 
with a subsequent risk of mechanical valve thrombosis and death.  
Thus, there is no perfect aortic valve prosthesis, and the type of prosthesis has to be 
carefully selected for each patient. In general, bioprostheses are recommended for older 
patients with more comorbidities, and mechanical valves are recommended for younger 
patients with a longer life expectancy. There are several different types and brands of 
aortic valve prostheses, which mainly differ in terms of structure and material. 
Mechanical Valve Prostheses 
Mechanical valves are either unileaflet, bileaflet, or caged ball valves, with the latter no 
longer in clinical use. The most commonly used mechanical valve is a bileaflet 
prosthesis made from pyrolytic carbon (Figure 1a). In case of aortic root replacement or 
concomitant aorta ascendens surgery, a Dacron graft with a mechanical valve sutured 
into one side can be used.  
Mechanical valves have excellent durability but require lifelong treatment with 
warfarin. The RE-ALIGN study was conducted to find an alternative to warfarin for 
these patients.49 The authors compared warfarin with dabigatran in patients with 
mechanical valves, but the study was terminated prematurely because the patients 
treated with dabigatran had a higher risk of major bleeding events and stroke than 
patients treated with warfarin had.49 The standard international normalized ratio (INR) 
target for patients with mechanical aortic heart valves is 2.0–3.0. The On-X valve (On-X 
Life Technologies Inc., Austin, Texas) was FDA-approved in 2002 and is designed to be 
safe with less anticoagulation. The PROACT study50 consist of two arms: the low-risk 
arm was performed to compare dual antiplatelet therapy (clopidogrel and aspirin) with 
the standard regimen of warfarin and aspirin, and the high-risk arm compared aspirin 
and warfarin in patients with INR targets of 1.5–2.0 versus 2.0–3.0. The low-risk arm 
was terminated because of a higher rate of ischemic stroke in the dual antiplatelet 
therapy group. In the high-risk arm, patients with INR targets of 1.5–2.0 did not show an 
increased risk of thromboembolic events and had a lower rate of bleeding events. The 
guidelines from the American Heart Association state that “a lower target INR of 1.5 to 
2.0 may be reasonable in patients with mechanical On-X AVR and no thromboembolic 
risk factors.”25 However, the guidelines from the European Society of Cardiology still 
recommend a median INR of 2.5 for these patients.10  
Apart from the disadvantage of lifelong anticoagulant treatment, the opening and 
closing of the mechanical valve can sometimes be audible outside the body, which some 
patients find disturbing. 
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Biological Valve Prostheses 
Biological prostheses are usually made from porcine aortic valve tissue or bovine 
pericardial tissue. The biological tissue is attached to a stent (for support) that is 
covered with a fine fabric to facilitate suturing of the prosthesis to the patient’s aortic 
root (Figures 1b and 1c).  
If the entire aortic root has to be replaced, for example in patients with endocarditis and 
extensive vegetations, stentless aortic root prostheses (e.g., the Freestyle prosthesis 
(Medtronic, Inc., Minneapolis, MN, USA) made from porcine heart valve tissue, Figure 
1d) or homografts can be used. Another option is the Ross procedure, in which the 
aortic root is replaced with the patient’s own pulmonary valve, and the pulmonary valve 
is replaced with a homograft. In these operations, the coronary arteries are usually 
reimplanted to the prosthetic aortic root.22 
During the last 15 years, sutureless, self-expanding aortic valve bioprostheses (also 
called rapid deployment valves) have been introduced, allowing for shorter 
cardiopulmonary bypass times and easier implantation (Figure 1e). Some studies 
reported promising initial results.51,52 However, other studies reported an increased 
risk of pacemaker implantation and disabling stroke in patients who received rapid 
deployment valves compared with conventional valves.53 The long-term function of 
these valves and their role in the treatment of aortic valve disease need to be evaluated 
further.  
The valve prostheses used for TAVI are usually made from either porcine or bovine 
tissue (Figure 1f). TAVI can be performed as a primary surgery or as a valve-in-valve 
procedure as an alternative to reoperation in failing biological valve prostheses.54 
Figure 1a-f. The St Jude Medical Regent mechanical55 (Abbott, St Paul, Minnesota, USA; upper left), the 
Perimount bovine (Edwards Lifesciences, Irvine, CA, USA; upper middle), the Mosaic porcine (Medtronic, Inc, 
Minneapolis, MN, USA; upper right), the Freestyle porcine (Medtronic, Inc, Minneapolis, MN, USA; lower left), 
the Perceval sutureless (LivaNova, Milan, Italy; lower middle), and the SAPIEN 3 transcatheter (Edwards 
Lifesciences, Irvine, CA, USA; lower right), aortic valve prostheses. Images reprinted with permission. 
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Bovine and Porcine Bioprostheses 
Several previous investigations reported advantages of pericardial bioprostheses 
compared with porcine aortic bioprostheses regarding hemodynamics, left ventricular 
mass regression, and PPM, factors considered to correlate with survival.4-6 However, no 
difference in long-term survival has been shown between these two types of 
bioprostheses.56,57 
The Aortic Perimount and Mosaic Bioprostheses 
The Carpentier-Edwards Perimount pericardial aortic bioprosthesis (Edwards 
Lifesciences, Irvine, CA, USA) and the Medtronic Mosaic porcine aortic bioprosthesis 
(Medtronic, Inc, Minneapolis, MN, USA) are two of the world’s most commonly used 
bioprostheses. 
The Perimount bioprosthesis (Figure 1b) has been in clinical use since 1981 and is 
made from bovine pericardial tissue mounted on a cobalt-chromium stent. It was 
designed to improve durability and decrease the incidence of SVD compared with 
previous bioprostheses. Repeated studies have shown that it has excellent long-term 
function.47,58 Patients who received the Perimount bioprosthesis have been reported to 
have a larger valve area, greater regression of left ventricular mass, and better valvular 
hemodynamics than patients with other bioprostheses have.4,6,59 However, no 
differences in survival or rate of reoperation between this type of prosthesis and other 
bioprostheses have been reported.6 
The Mosaic bioprosthesis (Figure 1c) is a stented porcine bioprosthesis that is treated 
with a combination of alpha-amino oleic acid and glutaraldehyde fixation at zero 
pressure to improve tissue durability and hemodynamic performance. It has been in 
clinical use since 1994, and follow-up studies have shown excellent results regarding 
both clinical outcomes and hemodynamic performance.60-62 However, a few studies 
have shown higher transvalvular gradients, a higher prevalence of PPM, and earlier 
reoperation caused by SVD with the Mosaic bioprosthesis than with other 
contemporary bioprostheses.4,63,64 Additionally, six cases of early bioprosthetic failure 
of the Mosaic bioprosthesis have been reported,65,66 which warrants further evaluation. 
Aortic Valve Replacement in Middle-Aged Patients 
There is no perfect aortic valve prosthesis, and many factors have to be considered 
before choosing the type of valve prosthesis for each particular patient. Patient age is 
one factor that should be taken into consideration. Other factors in this decision include 
the patient’s preference, bleeding susceptibility, expected lifespan, probability of 
compliance to warfarin therapy, comorbidities, size of the aortic annulus, and the wish 
to become pregnant in women of childbearing age. 
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Under the current guidelines, bioprostheses should be considered in patients older than 
65–70 years (65 and 70 years according to the European and American guidelines, 
respectively).10,25 Mechanical prostheses are considered to be reasonable alternatives in 
patients aged below 50–60 years (60 and 50 years according to the European and 
American guidelines, respectively).10,25 At ages 60–65 years (European guidelines) and 
50–70 years (American guidelines), both valve types are considered reasonable 
options.10,25 
Presumably because of the development of longer-lasting aortic bioprostheses, patient 
reluctance to warfarin treatment, and the development of TAVI as a possible alternative 
to reoperation, bioprostheses are increasingly used even in younger-aged patients.67,68 
However, there is no convincing scientific evidence to support this trend.  
Prior studies investigating survival and clinical outcomes following AVR with a 
mechanical or bioprosthetic valve in middle-aged patients have reported contradictory 
results. Some studies have shown better long-term clinical outcomes in patients who 
received a mechanical valve.69,70 Others reported no significant difference in long-term 
survival between patients who underwent AVR with a bioprosthesis compared with a 
mechanical valve.71,72  
In summary, the optimal prosthesis type in middle-aged patients remains unknown, 
and a large RCT would be needed for better guidance. Until then, several different 
factors need to be assessed, and every patient has to be assessed thoroughly and 
individually. 
Aortic Valve Replacement in Patients with Reduced Renal Function 
There is a well-known association between chronic kidney disease (CKD) and valvular 
heart disease, especially aortic stenosis.73,74 The imbalance in phosphate and calcium 
levels seen in patients with chronic renal failure is believed to cause a higher degree of 
calcification in the valvular annulus and leaflets, leading to aortic stenosis.73 
Additionally, patients with chronic renal failure are believed to be in a chronic 
inflammatory state, leading to accumulation of macrophages and T lymphocytes, 
eventually leading to increased calcium deposits73 and aortic stenosis.  
Patients with end-stage renal disease (ESRD) have a worse prognosis after cardiac 
surgery than patients with normal renal function have.75,76 They also have a higher risk 
of postoperative bleeding and a prolonged hospital stay following AVR.77,78 Aortic 
stenosis progresses more rapidly in patients with ESRD,74,79 and consequently, it is 
believed that calcification leading to SVD after AVR is more common in these patients. It 
has been debated whether or not these patients benefit more from a biological or 
mechanical valve prosthesis. It is hypothesized that these patients generally die from 
other causes before SVD becomes their main problem. In line with this hypothesis, most 
studies have not found a difference in mortality between patients with ESRD who 
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received a biological or mechanical aortic valve prosthesis.80,81 Even though moderately 
reduced kidney function is much more common than ESRD, studies investigating these 
patients’ prognosis after AVR are scarce.  
In many studies, creatinine values are used as an estimation of kidney function. 
However, the estimated glomerular filtration rate (eGFR) is a preferable indicator82,83 
because creatinine levels are influenced by age, muscle mass, and gender. eGFR has 
been shown to be a powerful predictor of outcome after valvular surgery.84 Two 
common methods to calculate eGFR are the Modification of Diet in Renal Disease 
formula and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
formula. These two methods are equally accurate in patients with CKD, but the CKD-EPI 
formula is believed to yield more accurate results in patients with eGFR values of >60 
mL/min/1.73m2.85
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AIMS 
This thesis aimed to investigate mortality, morbidity, and prosthetic valve function after 
AVR with different aortic valve prostheses.  
 
The specific aims of the individual studies were:  
Study I To analyze long-term, all-cause mortality in patients who underwent AVR 
and received Perimount versus Mosaic bioprostheses.  
Study II To analyze the hemodynamic function of patients who underwent AVR and 
received Mosaic bioprostheses. 
Study III To analyze the long-term, all-cause mortality in patients aged 50–69 years 
who underwent AVR with bioprostheses versus mechanical valve 
prostheses.  
Study IV To analyze the long-term, all-cause mortality after AVR in patients with 
moderately reduced versus normal kidney function. 
Study V To analyze the incidence and risk of PVE in patients who underwent AVR 
with bioprostheses versus mechanical valve prostheses.  
Study VI To systematically review the literature and perform a meta-analysis of 
long-term, all-cause mortality after AVR in patients who received bovine 
versus porcine bioprostheses.  
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PATIENTS AND METHODS 
Swedish National Registers 
SWEDEHEART 
The Swedish Web system for Enhancement and Development of Evidence-based care in 
Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) 
contains information about all patients in Sweden who: [1] received care at a coronary 
care unit, [2] were followed for secondary prevention after acute coronary syndrome, 
[3] underwent coronary angiography, [4] underwent percutaneous valve intervention, 
or [5] underwent open heart surgery. SWEDEHEART was started in 2009 by a merger 
of four already existing national quality registers: the Register of Information and 
Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA; since 1991), the 
Swedish Coronary Angiography and Angioplasty (SCAAR; since 1991/1992), the 
National Registry of Secondary Prevention (SEPHIA; since 2005), and the Swedish Heart 
Surgery Registry. The Swedish Heart Surgery Registry covers all patients who 
underwent cardiac surgery for any reason since 1992. The register has complete 
coverage from all eight hospitals that perform cardiac surgery in Sweden. The 
agreement between SWEDEHEART and medical records has been reported to be 93%–
97%.86-88  
National Patient Register 
The Swedish National Patient Register was founded in 1964 and has complete coverage 
since 1987. It is maintained by the Swedish National Board of Health and Welfare and 
covers more than 99% of all somatic and psychiatric hospital discharges, including 
patient data, geographic data, administrative data about the hospital stay, and medical 
data. A senior physician establishes the diagnosis at hospital discharge, and the 
diagnosis is then forwarded to the National Patient Register by computer. These 
routines are standardized in Sweden. The diagnoses used in the National Patient 
Register are based on the World Health Organization’s International Classification of 
Diseases (ICD). The validity of the register has been repeatedly shown to be high, with 
95% validity for primary diagnosis of heart failure and positive predictive values of 
98.6% for stroke and 98%–100% for myocardial infarction.89,90 
Longitudinal Integration Database for Health Insurance and Labor Market Studies 
The longitudinal integration database for health insurance and labor market studies 
(LISA) register is a national register maintained by Statistics Sweden that covers all 
individuals aged above 16 years in Sweden since 1990.91 It is updated annually and 
provides information about employment, education, income, country of birth, place of 
residence, parental countries of birth, and educational status.  
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Cause of Death Register 
The Swedish Cause of Death Register92 contains data since 1961 and includes the cause 
and date of death. Since 2012, the data have been obtained from the death certificates of 
all individuals who died in Sweden, regardless of whether the person died in Sweden or 
abroad and whether or not the person was registered in Sweden. Before 2012, only 
deaths of individuals registered in Sweden were included in the register. The Cause of 
Death Register is updated annually, and the diagnoses in the register are coded 
according to the ICD.   
Total Population Register 
The Total Population Register is a national register maintained by Statistics Sweden 
that covers all people registered in Sweden since 1968. The register is updated 
continuously and provides information about places of birth and residency, civil status, 
migration status, and dates of birth and death.93 
Swedish Personal Identity Number 
The personal identity number is a unique 10-digit number assigned to every Swedish 
citizen since 1947. The number consists of the year, month, and date of birth followed 
by a gender-specific four-digit number. The personal identity number allows 
crosslinking of a large number of Swedish quality registers and is therefore an 
invaluable tool in medical research.94 
Ethical Considerations 
Study I–V were approved by the regional Human Research Ethics Committee in 
Stockholm, Sweden. Informed consent for Study II was obtained from all patients who 
underwent additional echocardiography. Informed consent for Study I, III, IV and V was 
not obtained because these were large database studies. Study VI is a systematic review 
and meta-analysis for which ethical approval is not necessary. 
Study Design and Patient Population 
The study designs and patient populations of the included studies are summarized in 
Table 1. 
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Table 1. Methodological overview of Study I to VI. 
 Study I Study II Study III Study IV Study V Study VI 
Design 
Observational, population-based 
cohort study 
Observational, population-based,  
nationwide cohort study 
Systematic 
review and 
meta-
analysis 
Exposure 
Perimount vs. 
Mosaic aortic 
bioprosthesis 
Mosaic aortic  
bioprosthesis 
Biological vs. 
mechanical 
aortic 
prosthesis 
Moderately 
reduced vs. 
normal renal 
function 
Biological vs. 
mechanical 
aortic 
prosthesis 
Bovine vs. 
porcine 
aortic valve 
prosthesis 
Primary 
outcome 
All-cause 
mortality 
Long-term aortic 
valve 
hemodynamics 
All-cause mortality 
Incidence of 
PVE 
All-cause 
mortality 
Secondary 
outcomes 
Early mortality, 
aortic valve 
reoperation, 
and effect of 
PPM on late 
survival 
All-cause 
mortality; aortic 
valve 
reoperation, and  
rate of PPM and 
effect of PPM on 
late survival 
Stroke, 
 aortic valve 
reoperation, 
major 
bleeding 
Early 
mortality, 
major 
bleeding, 
aortic valve 
reoperation, 
and all-cause 
mortality 
bioprosthesis 
vs. 
mechanical 
Early PVE, 
late PVE, and 
all-cause 
mortality 
after PVE 
- 
Setting Karolinska University Hospital Nationwide 
Austria, 
Canada, 
USA, 
Sweden, 
England and 
Wales 
Period 2002-2010 2002-2008 1997-2013 1995-2012 1976-2013 
End of 
follow-up 
15 March 2013 1 October 2013 24 March 2014 
31 December 
2012 
- 
Statistical 
method 
Cox regression 
Cox 
regression, 
propensity-
score 
matching 
Cox regression 
Meta-
analysis 
PVE = prosthetic valve endocarditis, PPM = prosthesis-patient mismatch. 
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Study I 
Study I was a population-based cohort study. We included all patients who underwent 
AVR and received either Perimount or Mosaic bioprostheses at Karolinska University 
Hospital between 2002 and 2010. As a result of institutional directives, the Mosaic valve 
was mainly used between 2002 and 2004, and the Perimount valve was mainly used 
between 2005 and 2010. The primary outcome was all-cause mortality. The secondary 
outcomes were early mortality, aortic valve reoperation, and the effects of PPM on late 
survival. A flowchart containing the inclusion and exclusion criteria is shown in Figure 
2. 
Study II 
Study II was a descriptive, population-based cohort study. We included all patients who 
underwent AVR and received Mosaic bioprostheses at Karolinska University Hospital 
between 2002 and 2008. The primary outcome was hemodynamic function. The 
secondary outcomes were all-cause mortality, aortic valve reoperation, and the rate of 
PPM and its effects on survival. Valve hemodynamics were assessed as mean and peak 
pressure gradients (PPG) obtained from echocardiography. If the PPG was missing, it 
was calculated from the maximum transvalvular velocity according to the simplified 
Bernoulli equation. Early postoperative echocardiography was most commonly 
performed on the third day after surgery. All patients alive in August 2012 were offered 
                          
                          
                            
                          
                       
            
                    
     
                      
                  
                     
                  
       
                          
                     
                         
                  
                          
                       
            
                    
      
                     
         
                   
         
      
Figure 2 and 3. Flowcharts of Study I and II. 
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an additional transthoracic echocardiographic examination. In patients who were 
unwilling or unable to undergo the additional examination, information about 
hemodynamic function was obtained from the most recent echocardiography available 
in their medical records. A flowchart containing the inclusion and exclusion criteria is 
shown in Figure 3. 
Study III 
Study III was an observational, population-based, nationwide cohort study. We included 
all patients aged 50–69 years who underwent primary, isolated AVR with biological or 
mechanical prostheses in Sweden between 1997 and 2013. The primary outcome was 
all-cause mortality in patients who received biological versus mechanical valve 
prostheses. The secondary outcomes were the rates of aortic valve reoperation, stroke, 
major bleeding, and cardiovascular mortality. A flowchart containing the inclusion and 
exclusion criteria is shown in Figure 4. 
 
 
 
 
Figure 4. Flowchart of Study III. 
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Study IV 
Study IV was an observational, population-based, nationwide cohort study. We included 
all patients who underwent primary AVR with biological or mechanical prostheses in 
Sweden between 1997 and 2013. Patients were divided into two groups: the normal 
and moderately reduced kidney function groups. The primary outcome was all-cause 
mortality. The secondary outcomes were early mortality, aortic valve reoperation, and 
major bleeding events. We also compared all-cause mortality in patients with 
moderately reduced kidney function who received biological versus mechanical valve 
prostheses. A flowchart containing the inclusion and exclusion criteria is shown in 
Figure 5. 
 
 
 
Figure 5. Flowchart of Study IV. 
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Study V 
Study V was an observational, population-based, nationwide, cohort study. We included 
all patients who underwent AVR with biological or mechanical prostheses in Sweden 
between 1995 and 2012. The primary outcome was the incidence and risk of PVE in 
patients who received biological versus mechanical valve prostheses. The secondary 
outcomes were early endocarditis, late endocarditis, and all-cause mortality after PVE. A 
flowchart containing the inclusion and exclusion criteria is shown in Figure 6. 
 
 
 
 
 
Figure 6. Flowchart of Study V. 
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Study VI 
Study VI was a systematic review and meta-analysis comparing mortality after AVR 
with bovine versus porcine aortic valve prostheses. Quality assessment of the included 
studies was performed using a quality assessment tool based on relevance to our study 
that we created when writing the study protocol (before starting the literature search). 
The creation of the quality assessment tool was based on a systematic review of 86 
quality assessment tools for observational studies performed by Sanderson et al.95 A 
flowchart containing the inclusion and exclusion criteria is shown in Figure 7. 
 
 
 
Figure 7. Flowchart of Study VI. 
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Data Collection 
Study I–II 
Personal identity numbers and the Total Population Register were used to obtain 
information about survival status. Baseline and operative characteristics were obtained 
from medical records. For Study II, data on early and late (for those who did not 
undergo additional echocardiography) hemodynamic function were obtained from 
medical records.  
Study III–V 
The study population for Study III–V was obtained from the SWEDEHEART register, 
which was cross-linked with other national registers to obtain further patient data. 
Cross-linking of the national registers was possible thanks to individual Swedish 
personal identity numbers. The ICD codes and national health registers used for these 
studies are shown in Table 2.  
Study VI 
A systematic literature search was performed by two professional librarians at the 
Karolinska Institutet University Library. Abstracts and full texts were screened by two 
authors (Natalie Glaser and Ulrik Sartipy), and both authors included the same articles. 
Data extraction from the included studies was performed by the same two authors 
independently. We extracted the following information from each article: first author’s 
name, country, study design, time frame of recruitment, total number of patients, 
number of patients who received bovine and porcine valves, types of bovine and 
porcine valves, mean age of study population, statistical methods, unadjusted and 
adjusted hazard ratios (HR) and 95% confidence intervals (CI), confounders adjusted 
for, and years of follow-up.  
Definition and Calculation of Variables 
For the data sources and ICD codes used in Study III–V, see Table 2. 
All Studies 
Early mortality was defined as death within 30 days after surgery. Emergent surgery 
was defined as surgery within 24 hours of the decision to perform surgery. The formula 
used to calculate body mass index (BMI) was: (weight in kg)/(length in meters2). 
Study I–II 
The presence of PPM was evaluated by calculating the effective orifice area index using 
published in vivo measurements1 indexed to the patient’s BSA. BSA was calculated 
according to the Mosteller formula (BSA = √(((height)×weight)/3600)).96 Severe and  
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Table 2. Origin of variables and ICD codes for Study III-V.    
SWEDEHEART 
Variable ICD-9 ICD-10 
Study* 
III IV V 
Age      
Gender      
Biological valve prosthesis 
 FMD10    
3117 FMD33, FCA70    
 FMD20, FMD30    
Mechanical valve prosthesis 
 FMD00    
3116 FCA60    
Aortic valve reoperation      
Height      
Weight      
Preoperative serum 
creatinine 
     
Left ventricular ejection 
fraction 
     
Year of surgery      
Emergent surgery      
Previous cardiac surgery      
EuroSCORE      
LISA 
Variable 
  Study* 
III IV V 
Civil status      
Education      
Region of birth      
Cause of death Register 
Variable ICD-9 ICD-10 
Study* 
III IV V 
Date of death      
Cardiovascular death  
I10 to I15.9, I20 to I25.9, I44 to I45.9 
(except for I45.6 and I45.8), I46, I47.0 to 
I47.9, I48, I49, I50.0 to I50.9, I51.0 to 
I51.9 (except for I51.4), M219, R001, 
R008, R012, I61.0 to I61.9, I62.0, I62.9, 
I63.0 to I63.5, I63.8, I63.9, I64, I65.0 to 
I65.9, I66.0 to I66.9, I67.0, I67.2 to I67.4, 
I67.6, I67.8, I67.9, I70.0 to I70.9, I71.0 to 
I71.9, I72.0 to I72.9, I73.1, I73.8, I73.9, 
R960, R961 
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Table 2. Continued.     
National Patient Register 
Variable ICD-9 ICD-10 
Study*  
III IV V 
Myocardial infarction 410 I21 to I21.9    
Prior stroke at baseline 430 to 438 I60 to I69.9    
Postoperative stroke  
(primary diagnosis) 
 I60 to I64 
   
Heart failure 
428 I50 to I50.9    
425 I42-I43.9, I25.5, K76.1, I11.0, I13.0, I13.2    
Atrial fibrillation 427D I48 to I48.9    
Chronic obstructive 
pulmonary disease 
490 to 496 J44 to J44.9 
   
Hypertension 401 to 405 I10 to I15.9    
Hyperlipidemia 272 E78 to E78.9    
Peripheral vascular disease 440 to 446 I65 to I65.9, I71 to I71.9, I73.8, I73.9    
Alcohol abuse 291, 303, 571 F10 to F10.9, K70 to K70.9    
Liver disease 570 to 573 K70 to K77.9    
Cancer 140 to 208 C00 to C97.9    
Endocarditis 
421 I33, I33.9, I38.9    
421, 391B I33, I38, I39    
Diabetes mellitus 250 E10 to E14.9    
Major bleeding event 
285B, 430, 431, 
432, 456A, 
530H, 531A, 
531C, 531E, 
531G, 532A, 
532C, 532E, 
532G, 533A, 
533C, 533E, 
533G, 534A, 
534C, 534E, 
534G, 569D, 
578 
 
D629, I60, I61, I62, I850, K226, K250, 
K252, K254, K256, K260, K262, K264, 
K266, K270, K272, K274, K276, K280, 
K282, K284, K286, K290, K625, K920, 
K921, K922, I312, I230, J942, K661, M250, 
N421, N501A, N938, N939, N950, R041, 
R042, R048, R049, R31 
   
Prior percutaneous 
coronary intervention 
3080 FNG00-FNG06 
   
Drug abuse 304 F11-F16, F18-F19    
Cardiac implantable 
electronic device 
3093-3097, 
3157, 3170, 
V45A, V53D 
FPE00, FPE10, FPE20, FPE26, FPF00, 
FPF10, FPF20, FPG10, FPG20, FPD30, 
FPG33, Z45.0 
   
*Variables used in Study III-V marked with dark grey color. 
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moderate PPM were defined as effective orifice area index 0.65 cm2/m2 and 0.85 
cm2/m2, respectively. eGFR was calculated according to the Modification of Diet in Renal 
Disease formula (eGFR=(preoperative creatinine value/88.4)−1.154×age−0.203×0.742 
if female).97 Acute kidney injury was defined as a serum creatinine value after surgery 
of 26 mmol/L or more than that before surgery. Urgent surgery was defined as surgery 
within the same hospitalization period as the decision to perform surgery.  
In Study II, severe and moderate aortic stenosis were defined as MPG >40 mmHg and 
25–40 mmHg, respectively.  
Study III–V 
eGFR was calculated according to the CKD-EPI formula and the most recent 
preoperative creatinine value:85 
Women with creatinine ≤62 mol/L: (144+22 if black)×(creatinine/0.7)−0.329×0.993age 
Women with creatinine >62 mol/L: (144+22 if black)×(creatinine/0.7)−1.209×0.993age 
Men with creatinine ≤80 mol/L: (141+22 if black)×(creatinine/0.9)−0.411×0.993age 
Men with creatinine >80 mol/L: (141+22 if black)×(creatinine/0.9)−1.209×0.993age 
In Study IV, normal kidney function was defined as eGFR above 60 mL/min/1.73m2, and 
moderately reduced kidney function (corresponding to CKD stage III) was defined as 
eGFR 30–60 mL/min/1.73m2. 
In Study V, PVE was defined as first-time hospitalization for infective endocarditis. Early 
endocarditis was defined as first-time hospitalization for endocarditis more than 90 
days after surgery (to avoid including patients who underwent AVR because of 
endocarditis) and less than one year after surgery. Late endocarditis was defined as 
first-time hospitalization for infective endocarditis more than one year after surgery. 
Statistical Analysis 
Baseline characteristics were presented as proportions for categorical variables and as 
means and standard deviations (SD) for continuous variables in all studies.  
Data management and statistical analysis were performed using Stata (StataCorp LP 
College Station, TX, USA) version 12.1 (Study I), version 13.1 (Study II and III), version 
14.1 (Study IV), and version 14.2 (Study V and VI) and R (R Foundation for Statistical 
Computing, Vienna, Austria) version 3.0.2 (Study II), version 3.1.2 (Study III), version 
3.3.0 (Study IV), and version 3.3.2 (Study V). 
Cox Proportional Hazard Regression 
Cox regression was used in Study I–V to assess the association between exposure and 
outcome. The Cox proportional hazard model is a regression technique that allows for 
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univariate and multivariable adjustment while accounting for time-to-event. This 
method also includes information from censored patients (i.e., patients who were lost to 
follow-up) and patients who had not experienced the event of interest by the end of 
follow-up.98 Cox regression gives us the HR, which can be interpreted as the risk of 
having an event at each given time point. A Kaplan-Meier curve is commonly used to 
illustrate the proportion of patients in each group who have not yet experienced the 
event of interest at each time point. 
Competing Risks 
A competing risk is an event that eliminates an individual’s risk associated with the 
event of interest. For example, if the event of interest is aortic valve reoperation, and the 
patient dies, he or she can no longer go through a reoperation (i.e., death is a competing 
risk of aortic valve reoperation). The proportional hazards model of subdistribution 
proposed by Fine and Gray99 can account for competing risks and gives us the 
subdistribution HR (sHR), which is the risk of the event of interest at each given time 
point while accounting for competing risks.  
Propensity Scores  
Propensity methods can be used in nonrandomized, observational studies where 
patients who receive one treatment are different from those who receive another 
treatment (a bias called “confounding by indication”).100 For example, in our studies, 
older patients with more comorbidities are more likely to receive bioprostheses, 
whereas younger, healthier patients are more likely to receive mechanical valve 
prostheses. A propensity score of 0–1 is calculated based on patient characteristics to 
estimate the probability of receiving the treatment of interest. The propensity score can 
be used in different ways to obtain more comparable groups and hence reduce the risk 
of confounding by indication.  
Multiple Imputation 
Multiple imputation is a method to handle missing data. With this method, a missing 
variable for one patient is replaced with a value that is generated many times and then 
combined into one specific value. This specific value is estimated based on the 
assumption that data are missing at random (i.e., that the missing data are related to the 
observed data) and therefore can be estimated based on the observed data. Multiple 
imputation is advantageous because it allows for the analysis to retain statistical power 
and reduces selection bias resulting from not analyzing the results from patients with 
missing data. In Study III–V, we used multiple imputation by chained equations101 to 
handle missing data. We imputed and combined 25 datasets according to Rubin’s rules, 
and the event indicator and Nelson-Aalen estimator of the cumulative baseline hazard 
were included in the imputation model.102 
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Study I 
Person-time was calculated as time from the date of surgery until the date of death. 
Patients were censored at the date of death, end of follow-up (March 15th, 2013), date of 
aortic valve reoperation, or date of emigration. Cox proportional hazard regression was 
used to assess the association between baseline characteristics, including prosthetic 
type, and late survival. All variables with clinical or statistical significance (p<0.05) were 
included in the multivariable analysis. The Kaplan-Meier method was used to construct 
survival curves. The log-rank test was used to statistically assess differences in survival 
between patients who received Perimount and Mosaic prostheses. Information was 
missing for the following variables that were included in the multivariable analysis: left 
ventricular ejection fraction (LVEF; 2.5%), BMI and BSA (4%), and acute kidney injury 
(3%). The missing data were handled by assuming that patients with missing LVEF had 
normal LVEF and replacing missing BMI and BSA values with the mean BMI and BSA 
values, respectively, for male and female patients in our cohort.  
Study II 
The follow-up period for late hemodynamic function was counted from the date of 
surgery until the date of the most recent available echocardiography. The Kaplan-Meier 
method was used to construct survival curves, and the log-rank test was used to 
statistically assess differences in survival between patients with no, moderate, and 
severe PPM and between patients with no and moderate or severe aortic stenosis. Cox 
proportional hazard regression was used to analyze the association between baseline 
characteristics, PPM and MPG, and late survival. Patients contributed patient-time from 
the date of surgery until the date of death, date of aortic valve reoperation, or end of 
follow-up (October 1st, 2013). Information was missing for the following variables that 
were included in the multivariable analysis: eGFR (5%), LVEF (4%), acute kidney injury 
(5%), and MPG (15%). The cumulative incidence of aortic valve reoperation was 
estimated using a model proposed by Fine and Gray99 to account for the competing risk 
of death.  
Study III 
Follow-up for all-cause mortality ended on March 24th, 2014. For the secondary 
outcome measures of stroke, major bleeding event, and cardiovascular death, follow-up 
ended on December 31st, 2012, because information about these variables was only 
available until that date. Therefore, patients who underwent surgery during 2012 and 
2013 were excluded from the secondary outcome analyses. The Kaplan-Meier method 
was used to calculate cumulative survival and construct survival curves. Crude 
incidence rates and 95% CIs were calculated. To reduce the effects of confounding by 
indication, a propensity score-matched cohort was constructed in addition to the 
overall cohort. To construct the propensity scores, we used logistic regression including 
all variables in Table 6 (including hospital; see Results) as independent variables and 
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prosthesis type as the dependent variable. Separate models that did not include 
variables with missing data were constructed to maximize the number of included 
variables for each patient. We matched patients 1:1 with the nearest neighbor and 
applied a caliper width of 0.2×SD of the logit of the propensity score, which reduces the 
measured confounding by about 99%.100 Standardized differences were used to assess 
the balance between the groups post-matching, with a standard difference of less than 
10% considered negligible. In both the propensity score-matched and overall cohorts, 
Cox proportional hazards regression was used to estimate the association between 
valve type and mortality. For the propensity score-matched cohort, robust standard 
errors that allowed for intragroup correlation were used, and the model was stratified 
by year of surgery and hospital. BMI was modeled according to a restricted cubic spline 
model, and age was represented as a continuous variable, whereas all other variables 
were included as categorical variables. We also performed separate analyses in patients 
aged 50–59 years and 60–69 years, as well as in patients who underwent AVR before 
2006. For the overall cohort, unadjusted and multivariable-adjusted models were 
analyzed. In the multivariable analysis, we included all variables in Table 6 (see Results) 
and stratified by year of surgery and hospital. We also performed analyzes on the 
overall cohort including the propensity score using both the multivariable model and a 
separate model stratified into propensity score quintiles. To account for the competing 
risk of death, the model proposed by Fine and Gray99 was used to calculate the sHR and 
95% CI and graphically assess the cumulative incidence of the secondary outcomes. 
Multiple imputation by chained equations101 was used to handle the following missing 
data: eGFR (12%), LVEF (31%), and BMI (14%). We included 27 variables in the 
imputation model.  
Study IV 
Follow-up for all-cause mortality ended on March 24th, 2014. Follow-up for major 
bleeding events and aortic valve reoperation ended on December 31st, 2012, and 
December 31st, 2013, respectively, because information about these variables was only 
available until those dates. Cox proportional hazards regression was used to analyze the 
association between all-cause mortality and kidney function, and the association was 
expressed as HR and 95% CI. Crude incidence rates and 95% CI were also calculated. 
The Kaplan-Meier method was used to calculate cumulative survival and construct 
survival curves. All variables in Table 9 (see Results) were included in the multivariable 
analysis, and the model was stratified by hospital and year of surgery. To account for 
the competing risk of death, the sHR and 95% CI were calculated using the proportional 
hazards model of Fine and Gray99 to estimate the association between kidney function 
and secondary outcomes. In the analysis that compared patients with moderately 
reduced kidney function who received bioprostheses versus mechanical valve 
prostheses, a propensity score-matched cohort was constructed by the same method as 
in Study III. The logistic regression used to calculate each patient’s propensity score 
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included all variables in Table 9 (including hospital; see Results). BMI and age were 
included according to a restricted cubic spline model, and all other variables were 
represented as categorical variables. Multiple imputation by chained equations101 was 
used to handle the following missing data: LVEF (24%) and BMI (7%). The imputation 
model included all variables in Table 9 (See Results). 
Study V 
Person-time was calculated from the date of surgery until the date of diagnosis of PVE, 
death, or end of follow-up (December 31st, 2012, for PVE and March 24th, 2014, for 
death). Crude incidence rates and 95% CIs were calculated. To account for the 
competing risk of death, the cumulative incidence function was used to graph the 
absolute risk of PVE using the proportional hazards model of Fine and Gray.99 Cox 
proportional hazard regression was used to estimate the relative risk of PVE and 
mortality after PVE and was reported as HR and 95% CI. The Cox models were stratified 
by calendar year of surgery and hospital. Univariable analyses, age- and gender-
adjusted analyses, and multivariable models including all variables in Table 11 
(including year of surgery; see Results) were performed. Age and BMI were included 
according to a restricted cubic spline model, and all other variables were included as 
categorical variables. We also performed separate analyses restricted to patients in the 
following categories: age >60 years, surgery performed after 2003, excluding patients 
with a cardiac implantable electronic device, and excluding patients with a history of 
drug abuse. Multiple imputation by chained equations101 was used to handle the 
following missing data: eGFR (15.9%), LVEF (39.9%), and BMI (17.5%). The imputation 
model included 34 variables. 
Study VI 
The random-effects model was used to obtain the pooled HR and 95% CI values. HRs 
were converted so that porcine prostheses were the reference category in all studies. 
The most completely adjusted analysis was used. Cochrane’s Q test and the I2 test were 
used to explore signs of heterogeneity. The results of the I2 test were used to categorize 
heterogeneity as low (<50%), moderate (50%–75%), and high (>75%).103 Cochrane’s 
Q-test was considered significant if p<0.10. To evaluate the influence of each article on 
the overall effect size, one article at a time was omitted in a sensitivity analysis. A funnel 
plot was created to assess the influence of publication bias by both visual and statistical 
tests (Begg and Mazumdar’s104 and Egger’s105 tests).
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RESULTS 
The characteristics of the studies included in this thesis are summarized in Table 3. 
 
Table 3. Characteristics of Study I–VI. 
 Study I Study II Study III 
Number of patients 1219  355 4545  
Exposure group 
Mosaic 
bioprosthesis 
n = 355 (29%) 
Mosaic bioprosthesis 
n = 355 
Bioprosthesis 
n = 1832 (40%) 
Comparison group 
Perimount 
bioprosthesis 
n = 864 (71%) 
- 
Mechanical valve 
prosthesis 
n = 2713 (60%) 
Follow-up in years,  
mean (maximum)  
4.9 (11.1) 6.2 (11.5) 7.3 (17.2) 
 Study IV Study V Study VI 
Number of patients 13 102 26 580 49 190 
Exposure group 
Moderately reduced  
kidney function 
n = 3266 (25%) 
Bioprosthesis 
n = 16 426 (62%) 
Bovine prosthesis 
n = 32 235 (66%) 
Comparison group 
Normal kidney function 
n = 9836 (75%) 
Mechanical valve 
prosthesis 
n = 10 154 (38%) 
Porcine prosthesis 
n = 16 955 (34%) 
Follow-up in years,  
mean (maximum)  
6.2 (17.2) 6.2 (18.0) 3.6–7.4 (10.3-24.0) 
 
Study I 
Study Population 
We included all 1219 patients who underwent AVR at Karolinska University Hospital 
between 2002 and 2010. Of these, 864 (71%) and 355 (29%) patients received 
Perimount and Mosaic bioprostheses, respectively. The yearly numbers of implanted 
prostheses are shown in Figure 8. The baseline characteristics (Table 4) and implanted 
prosthetic sizes were similar between the groups. 
Survival 
The 1-, 5-, and 8-year survival rates were 93%, 78%, and 63% in the Perimount group 
and 92%, 80%, and 57% in the Mosaic group, respectively. There was no difference in 
all-cause mortality between the groups in the unadjusted (HR 1.00, 95% CI 0.80–1.26) 
or multivariable-adjusted (HR 0.85, 95% CI 0.65–1.11) analyses. The unadjusted 
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survival curve is shown in Figure 9. Early mortality was similar between the groups 
(3.7% vs. 4.8%, p=0.381). 
Secondary Objectives  
In total, 11 and 10 patients in the Perimount and Mosaic groups, respectively, required 
aortic valve reoperation (either surgical AVR or valve-in-valve TAVI) during follow-up. 
There was no statistically significant association between valve type and reoperation 
(p=0.745). Severe PPM was found in 48 (15%) and 47 (6%) patients in the Mosaic and 
Perimount groups, respectively (p<0.001). There was no significant association 
between severe PPM and long-term survival, either overall or in patients with 
depressed LVEF.  
     
Figure 8. Number of patients who underwent aortic valve replacement with a Perimount and a Mosaic valve 
per year.  
 
Figure 9. Kaplan-Meier estimated unadjusted survival curve for 1219 patients who underwent aortic valve 
replacement with a Perimount or a Mosaic prosthesis at Karolinska University Hospital between 2002 and 
2010. 
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Table 4. Baseline and operative characteristics in 1219 patients who underwent aortic valve 
replacement with Perimount or Mosaic bioprostheses between 2002 and 2010. 
 All patients Perimount Mosaic 
Number of patients (%) 1219 (100) 864 (71) 355 (29) 
Age, years (SD) 73.6 (9.6) 72.7 (9.6) 75.7 (9.4) 
Female (%) 40 38 46 
Body mass index (kg/cm2) 26.2 (4.5) 26.6 (4.5) 25.1 (4.1) 
eGFR (mL/min/1.73 m2) 71 (25) 73 (24) 66 (27) 
Diabetes mellitus 15 17 12 
Atrial fibrillation 14 14 16 
Hypertension 35 39 27 
Cerebrovascular disease 13 12 15 
Peripheral vascular disease 6 6 6 
Chronic obstructive pulmonary disease 7 7 7 
Prior percutaneous coronary 
intervention 
6 6 4 
Prior cardiac surgery 5 6 3 
Left ventricular ejection fraction (%)    
>50  73 74 70 
30-49 23 21 25 
<30 5 4 5 
Etiology of aortic valve disease    
Stenosis 84 84 84 
Regurgitation 12 12 11 
Stenosis and regurgitation 4 4 4 
Endocarditis 4 4 3 
Concomitant cardiac procedure 47 44 53 
Urgency    
Elective 86 85 89 
Urgent 13 14 10 
Emergent 1 2 1 
Aortic root enlargement 4 2 7 
Acute kidney injury 33 33 31 
Indexed effective orifice area    
> 0.85 (cm2/m2) 24 27 16 
0.65 - 0.85 (cm2/m2) 68 67 68 
<0.65 (cm2/m2) 8 6 15 
Number of patients (%) or mean (standard deviation). eGFR = estimated glomerular filtration rate.  
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Study II 
Study Population 
We included all 355 patients who underwent AVR with a Mosaic bioprosthesis at 
Karolinska University Hospital between 2002 and 2008. Baseline and operative 
characteristics are shown in Table 5. Concomitant procedures (most often coronary 
artery bypass grafting) were performed in approximately half of the patients.  
Hemodynamic Performance 
At early echocardiography, the mean PPG of the entire cohort was 39.9 mmHg (SD 
14.4), and the mean MPG was 21.1 mmHg (SD 7.7). During late echocardiography, the 
mean PPG was 38.6 mmHg (SD 15.6), and the mean MPG was 22.5 mmHg (SD 10.1). 
Early and late echocardiographic data were available for 340 (96%) and 161 (45%) 
patients, respectively. The mean PPG and MPG during early and late echocardiography 
is shown according to valve size in Figure 10. Of the patients alive in August 2012, 89 
agreed to undergo additional transthoracic echocardiography, and 57 actually 
underwent the examination. An external cardiologist performed the additional 
echocardiography according to a predefined study protocol. During late 
echocardiography, six and 40 patients had an MPG >40 mmHg and 25 mmHg, 
corresponding to severe and moderate aortic stenosis, respectively. An MPG 25 mmHg 
was not associated with increased mortality (p = 0.702; Figure 11). 
Secondary Objectives 
Mortality within 30 days after surgery was 4.8%, and the unadjusted 1-, 5-, and 10-year 
survival rates were 92%, 79%, and 42%, respectively. In total, 10 patients (2.8%) 
underwent aortic valve reoperation (surgical AVR or TAVI) during follow-up. The 
unadjusted cumulative incidence of aortic valve reoperation at 1, 5, and 10 years was 
0.3%, 1.7%, and 3.1%, respectively. Moderate and severe PPM were found in 250 (70%) 
and 49 (14%) patients, respectively. Moderate or severe PPM was not associated with 
increased mortality (p=0.194; Figure 11).  
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Table 5. Baseline and operative characteristics in 355 patients who underwent aortic valve 
replacement with Medtronic Mosaic bioprostheses between 2002 and 2008. 
Number of patients (%)  355 (100)  
Age, years (SD)  75.7 (9.4)  
Female  46  
Body mass index (kg/cm2), mean (SD)  25.1 (4.1)  
eGFR (mL/min/1.73 m2), mean (SD)  69 (23)  
Diabetes mellitus  12  
Atrial fibrillation  16  
Hypertension  27  
Cerebrovascular disease  15  
Peripheral vascular disease  6  
Chronic obstructive pulmonary disease  7  
Prior percutaneous coronary intervention  4  
Prior cardiac surgery  3  
Left ventricular ejection fraction    
>50   70  
30-49  25  
<30  5  
Endocarditis  3  
Concomitant cardiac procedure  53  
Urgency    
Elective  89  
Urgent  10  
Emergent  1  
Aortic root enlargement  7  
Aortic cross clamp time, mean (SD)  78 (28)  
Extracorporeal circulation, mean (SD)  109 (39)  
Days in the ICU, mean  2.4  
Days in the hospital, mean  8.9  
Acute kidney injury  31  
Acute kidney injury requiring dialysis  2.6  
Indexed effective orifice area    
> 0.85 (cm2/m2)  16  
0.65 - 0.85 (cm2/m2)  70  
<0.65 (cm2/m2)  14  
Early postoperative echocardiography    
Peak pressure gradient, mean mmHg (SD)  39.2 (16.3)  
Mean pressure gradient, mean mmHg (SD)  22.8 (10.6)  
Numbers are percentages unless otherwise stated.  
SD = standard deviation, eGFR = estimated glomerular filtration rate.   
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Figure 11. Kaplan-Meier estimated unadjusted survival curve in patients who underwent aortic valve 
replacement with a Mosaic bioprosthesis at Karolinska University Hospital between 2002 and 2008. Patients 
divided by prosthesis-patient mismatch in the left-hand graph, and by mean pressure gradient at early 
echocardiographic follow-up in the right-hand graph.  
  
Figure 10. The mean peak and mean pressure gradient at early and late echocardiography according to 
valve size. 
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Study III 
Study Population 
We included all 4545 patients who underwent primary, isolated AVR in Sweden 
between 1997 and 2013. Of these, 2713 (60%) received a mechanical valve prosthesis, 
and 1832 (40%) received a bioprosthesis. The use of bioprostheses increased from 17% 
in 1997–2002 to 58% in 2006–2013, even though patient age remained similar 
throughout the entire study period (Figure 12). In the overall cohort, patients who 
received bioprostheses were generally older and had more comorbidities (Table 6). In 
the propensity score-matched cohort, baseline characteristics were well balanced 
(Table 7). 
Survival 
In the overall cohort, patients with mechanical valve prostheses had better survival 
than patients with bioprostheses had (adjusted HR 1.30, 95% CI 1.09–1.56). Analyses of 
the propensity score-matched cohort showed similar results (HR 1.34, 95% CI 1.09–
1.66, p=0.006), as illustrated in Figure 13. The event rates and relative risks are shown 
in Table 8. In the propensity score-matched cohort, the 5-, 10-, and 15-year survival 
were 92%, 79%, and 59% in the mechanical valve group and 89%, 75%, and 50% in the 
bioprosthetic valve group, respectively. A subgroup analysis of 574 propensity score-
matched patients aged 50–59 years showed significantly higher survival rates in 
patients with mechanical valve prostheses (HR 1.67, 95% CI 1.06–2.61, p=0.026). In 
1502 propensity score-matched patients aged 60–69 years, no difference in survival 
was found between the groups who received mechanical versus biological prostheses 
(HR 1.08, 95% CI 0.85–1.36, p=0.539).  
Secondary Objectives in the Propensity Score-Matched Cohort 
There was no difference in the rate of stroke or cardiovascular mortality between 
patients who received mechanical and biological prostheses (sHR 1.04, 95% CI 0.72–
1.50; and sHR 1.00, 95% CI 0.67–1.50, respectively). The risk of aortic valve reoperation 
was higher (sHR 2.36, 95% CI 1.42–3.94), but the risk of major bleeding events was 
lower (sHR 0.49, 95% CI 0.34–0.70), in patients who received bioprostheses compared 
with those who received mechanical valve prostheses. The cumulative incidence rates 
of the secondary outcomes are illustrated in Figure 14. 
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Table 6. Baseline characteristics in 4545 patients aged 50-69 who underwent aortic valve replacement 
with mechanical or biological aortic valve prostheses between 1997 and 2013. 
 
All patients 
(N = 4545) 
Mechanical 
prosthesis 
(N = 2713) 
Biological 
prosthesis 
(N = 1832) 
Standardized 
difference 
(%) 
p-
value 
Age, years, mean (SD) 61.4 (5.3) 59.9 (5.1) 63.7 (4.7) 77 <0.001 
Female sex 1487 (32.7%) 848 (31.3%) 639 (34.9%) 7.7 0.011 
Civil status      
Not married or   
cohabiting 
1723 (37.9%) 993 (36.6%) 730 (39.8%) 6.7 0.028 
Education     0.12 
>12 years 971 (21.7%) 551 (20.7%) 420 (23.3%) 6.2  
Region of birth      
Non-Nordic countries 290 (6.4%) 167 (6.2%) 123 (6.7%) 2.3 0.45 
Body mass index (kg/cm2), 
mean (SD)  
27.2 (4.7) 27.2 (4.6) 27.1 (4.7) 1.6 0.63 
Diabetes mellitus 557 (12.3%) 265 (9.8%) 292 (15.9%) 18.5 <0.001 
Atrial fibrillation 389 (8.6%) 237 (8.7%) 152 (8.3%) 1.6 0.60 
Hypertension 925 (20.4%) 450 (16.6%) 475 (25.9%) 23.0 <0.001 
Hyperlipidemia 376 (8.3%) 202 (7.4%) 174 (9.5%) 7.4 0.014 
Stroke 269 (5.9%) 135 (5.0%) 134 (7.3%) 9.7 0.001 
Peripheral vascular disease 168 (3.7%) 83 (3.1%) 85 (4.6%) 8.2 0.006 
Chronic pulmonary disease 306 (6.7%) 137 (5.0%) 169 (9.2%) 16.3 <0.001 
Prior myocardial infarction 275 (6.1%) 151 (5.6%) 124 (6.8%) 5.0 0.095 
Prior PCI 110 (2.4%) 43 (1.6%) 67 (3.7%) 13.0 <0.001 
Prior major bleeding event 175 (3.9%) 66 (2.4%) 109 (5.9%) 17.6 <0.001 
Alcohol dependency 154 (3.4%) 54 (2.0%) 100 (5.5%) 18.4 <0.001 
Liver disease 68 (1.5%) 26 (1.0%) 42 (2.3%) 10.6 <0.001 
Cancer 256 (5.6%) 110 (4.1%) 146 (8.0%) 16.5 <0.001 
eGFR (mL/min/1.73 m2)     0.006 
>60 3392 (84.3%) 1990 (85.8%) 1402 (82.3%) 9.8  
<15* 60 (1.5%) 24 (1.0%) 36 (2.1%) 8.7  
Heart failure 633 (13.9%) 376 (13.9%) 257 (14.0%) 0.5 0.87 
Left ventricular ejection 
fraction 
    0.59 
>50 % 2441 (77.5%) 1204 (76.9%) 1237 (78.0%) 2.7  
Endocarditis 357 (7.9%) 199 (7.3%) 158 (8.6%) 4.8 0.11 
Emergent surgery 81 (1.8%) 35 (1.3%) 46 (2.5%) 8.9 0.002 
Year of surgery     <0.001 
Data are n (%) unless otherwise noted.*This category includes patients on preoperative dialysis 
eGFR = estimated glomerular filtration rate, PCI = percutaneous coronary intervention, SD = standard 
deviation.  
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Table 7. Baseline characteristics after propensity score matching in 2198 patients aged 50-69 who 
underwent AVR with mechanical or biological aortic valve prostheses between 1997 and 2013. 
 Mechanical 
prosthesis 
(N = 1099) 
Biological 
prosthesis 
(N = 1099) 
Standardized 
difference (%) 
P Value 
Age, years, mean (SD) 62.3 (4.5) 62.1 (5.1) 3.3 0.44 
Female sex 380 (34.6%) 352 (32.0%) 5.4 0.21 
Civil status     
Not married or cohabiting 421 (38.3%) 426 (38.8%) 0.9 0.83 
Education    0.89 
>12 years 233 (21.2%) 233 (21.2%) 0.0  
Region of birth     
Non-Nordic countries 69 (6.3%) 75 (6.8%) 2.2 0.60 
Body mass index (kg/cm2), 
mean (SD) 
27.2 (4.8) 27.1 (4.9) 2.1 0.64 
Diabetes mellitus 146 (13.3%) 147 (13.4%) 0.3 0.95 
Atrial fibrillation 89 (8.1%) 108 (9.8%) 6.1 0.16 
Hypertension 242 (22.0%) 236 (21.5%) 1.3 0.76 
Hyperlipidemia 101 (9.2%) 95 (8.6%) 1.9 0.65 
Stroke 60 (5.5%) 70 (6.4%) 3.9 0.37 
Peripheral vascular disease 42 (3.8%) 37 (3.4%) 2.4 0.57 
Chronic pulmonary disease 69 (6.3%) 74 (6.7%) 1.8 0.67 
Prior myocardial infarction 60 (5.5%) 68 (6.2%) 3.1 0.47 
Prior PCI 29 (2.6%) 18 (1.6%) 6.9 0.10 
Prior major bleeding event 33 (3.0%) 44 (4.0%) 5.4 0.20 
Alcohol dependency 39 (3.5%) 51 (4.6%) 5.5 0.20 
Liver disease 13 (1.2%) 19 (1.7%) 4.6 0.29 
Cancer 61 (5.6%) 57 (5.2%) 1.6 0.71 
eGFR (mL/min/1.73 m2)    0.81 
>60 842 (83.9%) 848 (83.2%) 1.7  
<15* 11 (1.1%) 13 (1.3%) 1.7  
Heart failure 141 (12.8%) 165 (15.0%) 6.3 0.14 
Left ventricular ejection 
fraction 
   0.91 
>50 % 656 (78.5%) 674 (77.6%) 2.0  
Endocarditis 92 (8.4%) 98 (8.9%) 1.9 0.65 
Emergent surgery 21 (1.9%) 21 (1.9%) 0.0 1.00 
Year of surgery    0.88 
Data are n (%) unless otherwise noted. *This category includes patients on preoperative dialysis 
eGFR = estimated glomerular filtration rate; PCI = percutaneous coronary intervention, SD = 
standard deviation. 
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Figure 12. Number of patients aged 50–69 years who underwent aortic valve replacement with 
bioprosthetic or mechanical valves in Sweden per year.  
 
Table 8. Event rates and relative risks for all-cause mortality in patients aged 50-69 who 
underwent aortic valve replacement with a mechanical or a biological aortic valve prosthesis. 
 Mechanical  Biological 
 
Events/
PY 
Crude 
rate  
(95% CI) 
per 
1000 PY 
HR  
(95% CI) 
 Events/PY 
Crude 
rate 
(95% CI) 
per 
1000 PY 
HR (95% CI) 
Propensity score 
matched cohort 
n = 2198 
180/ 
7324 
25  
(21-28) 
1.00 
 
217/7099 
31  
(27-35) 
1.34 (1.09-1.66) 
        
Overall cohort 
n = 4545 
527/ 
23826 
22  
(20-24) 
 
 
289/9163 
32  
(28-35) 
 
Unadjusted   1.00 
 
  1.67 (1.44-1.94) 
Multivariable 
adjusted model* 
  1.00 
 
  1.30 (1.09-1.56) 
Multivariable 
adjusted + PS 
  1.00 
 
  1.32 (1.10-1.58) 
Multivariable 
adjusted + stratified 
based on PS quintiles 
  1.00 
 
  1.32 (1.07-1.62) 
PS = propensity score, PY = person-years, CI = confidence interval, HR = hazard ratio. 
*Multivariable adjustment was made for all variables in Table 6. 
  41 
 
 
Figure 13. Kaplan-Meier estimated survival curve in propensity score-matched patients aged 50–69 years 
who underwent aortic valve replacement in Sweden between 1997 and 2013. 
 
 
Figure 14. Cumulative incidence of stroke, aortic valve reoperation, major bleeding events, and 
cardiovascular death in propensity score–matched patients aged 50–69 years who underwent aortic valve 
replacement with mechanical versus biological valve prostheses.  
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Study IV 
Study Population 
We included all 13 102 patients with available preoperative creatinine values and eGFR 
>30 mL/min/1.73m2 who underwent primary AVR in Sweden between 1997 and 2013. 
Of these, 9836 (75%) had normal kidney function, and 3266 (25%) had moderately 
reduced kidney function. Of the patients with moderately reduced kidney function, 
2582 (79%) received bioprostheses and 684 (21%) received mechanical valve 
prostheses. Patients with moderately reduced kidney function were generally older and 
had more comorbidities (Table 9). In the propensity score-matched analysis of patients 
with moderately reduced kidney function who received bioprostheses versus 
mechanical valve prostheses, the baseline characteristics were well balanced. 
Survival 
The 5-, 10-, and 15-year survival rates were 89%, 73%, and 55% in patients with 
normal kidney function and 76%, 48%, and 25% in patients with moderately reduced 
kidney function, respectively. Patients with normal kidney function had significantly 
better survival than patients with moderately reduced kidney function had (adjusted 
HR 1.28, 95% CI 1.18–1.38, p<0.001). The event rates and relative risks are shown in 
Table 10. The unadjusted Kaplan-Meier estimated survival curves for both groups are 
shown in Figure 15. Early mortality was 1.23% and 3.52% in patients with normal and 
moderately reduced kidney function, respectively (HR 1.87, 95% CI 1.39–2.51).  
Secondary Objectives 
The multivariable analysis showed a nonsignificantly higher risk of major bleeding 
events (sHR 1.18, 95% CI 1.00–1.39, p = 0.051) and a lower risk of aortic valve 
reoperation (sHR 0.54, 95% CI 0.38–0.79, p=0.001) in patients with moderately 
reduced kidney function. The cumulative incidence of major bleeding events and aortic 
valve reoperation are shown in Figure 16. In 3266 patients with moderately reduced 
kidney function, the multivariable analysis showed no difference in all-cause mortality 
between those who received biological versus mechanical valve prostheses (HR 0.86, 
95% CI 0.73–1.01). Analysis of a propensity score-matched cohort of 480 patient-pairs 
also showed no such difference (HR 0.85, 95% CI 0.70–1.03). The Kaplan-Meier 
estimated survival curve for the propensity score-matched cohort is shown in Figure 
17. 
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Table 9. Baseline characteristics in 13 102 patients with moderately reduced or normal kidney function 
who underwent aortic valve replacement in Sweden between 1997 and 2013.  
 
All patients 
n = 13 102 
Normal kidney 
function 
n = 9836 (75%) 
Moderately reduced 
kidney function 
n = 3266 (25%) 
Age, years, mean (SD) 66.8 (12.9) 64.3 (13.1) 74.4 (8.5) 
Female sex 5222 (39.9%) 3441 (35.0%) 1781 (54.5%) 
Civil status:  Not married or 
cohabiting 
5251 (40.1%) 3956 (40.2%) 1295 (39.7%) 
Education >12 years 2413 (18.4%) 1979 (20.1%) 434 (13.3%) 
Region of birth:  Non-Nordic 
countries 
769 (5.9%) 610 (6.2%) 159 (4.9%) 
Body mass index (kg/cm2), 
mean (SD) 
26.7 (4.5) 26.7 (4.5) 26.8 (4.7) 
Biological valve prosthesis 8258 (63.0%) 5676 (57.7%) 2582 (79.1%) 
Diabetes mellitus 1713 (13.1%) 1164 (11.8%) 549 (16.8%) 
Atrial fibrillation 1850 (14.1%) 1151 (11.7%) 699 (21.4%) 
Hypertension 3210 (24.5%) 2142 (21.8%) 1068 (32.7%) 
Hyperlipidemia 1061 (8.1%) 782 (8.0%) 279 (8.5%) 
Stroke 1131 (8.6%) 769 (7.8%) 362 (11.1%) 
Peripheral vascular disease 1076 (8.2%) 805 (8.2%) 271 (8.3%) 
Chronic pulmonary disease 992 (7.6%) 705 (7.2%) 287 (8.8%) 
Prior myocardial infarction 906 (6.9%) 569 (5.8%) 337 (10.3%) 
Prior PCI 515 (3.9%) 350 (3.6%) 165 (5.1%) 
Prior major bleeding event 620 (4.7%) 406 (4.1%) 214 (6.6%) 
Alcohol dependency 272 (2.1%) 223 (2.3%) 49 (1.5%) 
Liver disease 115 (0.9%) 83 (0.8%) 32 (1.0%) 
Cancer 930 (7.1%) 622 (6.3%) 308 (9.4%) 
eGFR (mL/min/1.73 m2)    
45 to 60 2377 (18.1%) - 2377 (72.8%) 
30 to 45 889 (6.8%) - 889 (27.2%) 
Heart failure 2176 (16.6%) 1284 (13.1%) 892 (27.3%) 
Left ventricular ejection 
fraction >50 
7564 (76.3%) 5979 (77.7%) 1585 (71.3%) 
Endocarditis 720 (5.5%) 565 (5.7%) 155 (4.7%) 
Emergent surgery 215 (1.6%) 162 (1.6%) 53 (1.6%) 
Isolated AVR 10869 (83.0%) 7934 (80.7%) 2935 (89.9%) 
Year of surgery: 2007 to 2013 6748 (51.5%) 5413 (55.0%) 1335 (40.9%) 
Data are n (%) unless otherwise noted.  
SD = standard deviation, PCI = percutaneous coronary intervention, eGFR = estimated glomerular 
filtration rate.  
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Figure 15. Kaplan-Meier estimated unadjusted survival in 13 102 patients with moderately reduced 
or normal kidney function who underwent aortic valve replacement in Sweden between 1997 and 
2013. 
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Figure 16. Cumulative incidence of major bleeding (left) and aortic valve reoperation (right) in 13 102 
patients with moderately reduced or normal kidney function who underwent aortic valve replacement in 
Sweden between 1997 and 2013. 
 
 
 
 
 
 
 
Figure 17. Kaplan-Meier estimated survival in 960 propensity score-matched patients with moderately 
reduced kidney function who underwent aortic valve replacement and received biological or mechanical 
prostheses in Sweden between 1997 and 2013.   
 46 
Study V 
Study Population 
We included all 26 580 patients who underwent primary AVR in Sweden between 1995 
and 2012. Of these, 16 426 (62%) received biological valve prostheses, and 10 154 
(38%) received mechanical valve prostheses. The yearly numbers of implanted valve 
prostheses is shown in Figure 18. The use of biological valve prostheses increased 
during the study period. Baseline characteristics according to prosthesis type are shown 
in Table 11.  
Prosthetic Valve Endocarditis 
In total, 940 (3.5%) patients were hospitalized for infective endocarditis during follow-
up. During the total follow-up time, the incidence rate of PVE was 0.57% (95% CI 0.54–
0.61) per person-year. Among patients with biological and mechanical valve prostheses, 
574 (3.5%) and 366 (3.6%) were hospitalized for PVE, respectively. The risks of both 
early and late PVE were higher in patients with bioprostheses (adjusted HR 1.54, 95% 
CI 1.31–1.74). Separate analyses in patients aged >60 years, patients who had surgery 
after 2003, all patients excluding those with cardiac implantable electronic devices, and 
all patients excluding those with a history of drug abuse showed similar results. The 
event rates, incidence rates, and relative risks of PVE are shown in Table 12. The 
cumulative incidence of PVE according to the type of valve prosthesis is shown in Figure 
19. Other factors associated with an increased risk of PVE were male sex, concomitant 
surgical procedures, diabetes mellitus, a cardiac implantable electronic device, drug 
abuse, peripheral vascular disease, CKD stage 5, surgery for infective endocarditis and 
emergent surgery.  
Mortality after Prosthetic Valve Endocarditis 
Of the 940 patients hospitalized for PVE, 377 of 574 (66%) and 186 of 366 (51%) 
patients in the biological and mechanical valve groups died during follow-up, 
respectively. Cumulative survival rates after PVE are shown in Figure 20. In the 
unadjusted analysis, the risk of death after PVE was higher in patients with 
bioprostheses (HR 1.64, 95% CI 1.37–1.96, p<0.001). In the multivariable-adjusted 
analysis, there was no difference in the risk of death after PVE between the two types of 
prostheses (HR 1.01, 95% CI 0.76–1.34, p=0.952). Of 940 patients hospitalized for PVE, 
108 (12%) underwent an aortic valve reoperation. Of these 108 patients, 13 (12%) died 
within 30 days. Among the 832 patients who were treated conservatively, 140 (17%) 
died within 30 days after the initial diagnosis of PVE. There was no statistically 
significant difference in 30-day mortality between those who underwent surgery and 
those who were treated conservatively. 
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Table 11. Baseline characteristics in 26 580 patients who underwent AVR with mechanical or biological 
aortic valve prostheses in Sweden between 1995 and 2012.  
 
All patients 
N = 26 580 
Mechanical valve 
prosthesis 
N = 10 154 (38%) 
Biological valve 
prosthesis 
N = 16 426 (62%) 
Age, years, mean (SD) 69.1 (11.8) 61.0 (11.7) 74.1 (8.6) 
Female sex 9975 (37.5%) 3058 (30.1%) 6917 (42.1%) 
Civil status: Not married or 
cohabiting 
10958 (41.2%) 4381 (43.1%) 6577 (40.0%) 
Education >12 years 3895 (14.7%) 1786 (17.6%) 2109 (12.8%) 
Region of birth: Non-Nordic 
countries 
1391 (5.2%) 643 (6.3%) 748 (4.6%) 
Body mass index, mean (SD) 26.6 (4.4) 26.9 (4.5) 26.5 (4.4) 
Cardiac implantable 
electronic device 
667 (2.5%) 202 (2.0%) 465 (2.8%) 
Drug abuse 98 (0.4%) 38 (0.4%) 60 (0.4%) 
Diabetes mellitus 4117 (15.5%) 1172 (11.5%) 2945 (17.9%) 
Atrial fibrillation 3967 (14.9%) 1348 (13.3%) 2619 (15.9%) 
Hypertension 6308 (23.7%) 1548 (15.2%) 4760 (29.0%) 
Hyperlipidemia 2377 (8.9%) 689 (6.8%) 1688 (10.3%) 
Stroke 2435 (9.2%) 674 (6.6%) 1761 (10.7%) 
Peripheral vascular disease 2522 (9.5%) 1044 (10.3%) 1478 (9.0%) 
Chronic pulmonary disease 1909 (7.2%) 495 (4.9%) 1414 (8.6%) 
Prior myocardial infarction 3752 (14.1%) 1004 (9.9%) 2748 (16.7%) 
Prior PCI 1993 (7.5%) 843 (8.3%) 1150 (7.0%) 
Prior major bleeding event 1340 (5.0%) 284 (2.8%) 1056 (6.4%) 
Alcohol dependency 457 (1.7%) 165 (1.6%) 292 (1.8%) 
Liver disease 226 (0.9%) 64 (0.6%) 162 (1.0%) 
Cancer 1901 (7.2%) 408 (4.0%) 1493 (9.1%) 
eGFR (mL/min/1.73 m2)    
>60 15287 (68.4%) 6209 (79.7%) 9078 (62.3%) 
      <15 or dialysis 228 (1.0%) 69 (0.9%) 159 (1.1%) 
Heart failure 5065 (19.1%) 1639 (16.1%) 3426 (20.9%) 
Left ventricular ejection 
fraction >50 
11600 (72.6%) 3317 (74.2%) 8283 (72.0%) 
Preoperative endocarditis 462 (1.7%) 244 (2.4%) 218 (1.3%) 
Surgery for endocarditis 964 (3.6%) 456 (4.5%) 508 (3.1%) 
Emergent surgery 541 (2.0%) 300 (3.0%) 241 (1.5%) 
Isolated AVR 13383 (50.3%) 5200 (51.2%) 8183 (49.8%) 
Data are n (%) unless otherwise stated. AVR = aortic valve replacement, SD = standard deviation,  
PCI = percutaneous coronary intervention, eGFR = estimated glomerular filtration rate. 
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Figure 18. Number of patients who underwent aortic valve replacement with biological or mechanical valve 
prostheses in Sweden between 1995 and 2012. 
  
 
Table 12. Event rates and risks for prosthetic valve endocarditis in 26 580 patients who underwent 
aortic valve replacement with a mechanical or a biological valve prosthesis in Sweden from 1995 to 
2012. 
 Overall cohort 
n = 26 580 
Mechanical 
n = 10 154 (38%) 
Biological 
n = 16 426 (62%) 
 
Events/P
Y 
Crude rate 
(95% CI) per 
100 PY 
Events
/PY 
Crude 
rate 
(95% 
CI) per 
100 PY 
HR 
(95% 
CI) 
Events
/PY 
Crude 
rate 
(95% 
CI) per 
100 PY 
HR (95% CI) 
Total follow-
up time 
940/ 
164168 
0.57  
(0.54-0.61) 
366/ 
81345 
0.45  
(0.41-
0.50) 
 
574/ 
82823 
0.69  
(0.64-
0.75) 
 
Follow-up time 
(years) 
       
0-1 
240/ 
24309 
0.99  
(0.87-1.12) 
67/ 
9970 
0.70  
(0.55-
0.89) 
 
173/ 
15659 
1.17  
(1.01-
1.36) 
 
1-5 
391/ 
74068 
0.53  
(0.48-0.58) 
140/ 
36036 
0.43  
(0.37-
0.51) 
 
251/ 
48497 
0.60  
(0.53-
0.68) 
 
5-10 
229/ 
48286 
0.47  
(0.42-0.54) 
101/ 
34622 
0.38  
(0.31-
0.46) 
 
128/ 
35178 
0.59  
(0.50-
0.70) 
 
10-15 
75/ 
15898 
0.47  
(0.38-0.59) 
53/ 
20369 
0.47  
(0.36-
0.61) 
 
22/ 
1938 
0.49  
(0.32-
0.74) 
 
Unadjusted     1.00   
1.51  
(1.31-1.74) 
Adjusted for 
age and sex 
    1.00   
1.63  
(1.37-1.94) 
Multivariable 
adjusted 
model* 
    1.00   
1.54  
(1.29-1.83) 
PY = person-years, CI = confidence interval, HR = hazard ratio. 
*The multivariable model included all variables in Table 11. 
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Figure 19. Cumulative incidence of prosthetic valve endocarditis in 26 580 patients who underwent aortic 
valve replacement with biological or mechanical valve prostheses in Sweden between 1995 and 2012. 
 
 
         
 
Figure 20. Cumulative survival in 940 patients with prosthetic valve endocarditis after aortic valve 
replacement with biological versus mechanical valve prostheses. 
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Study VI 
After exclusion of 1599 articles that did not meet the inclusion criteria, seven articles 
were included. The flow diagram is shown in Figure 7 (see Methods), and selected 
characteristics of the included studies are shown in Table 13. In total, the included 
articles comprised 49 190 patients, of which 32 235 (66%) and 16 955 (34%) received 
bovine and porcine prostheses, respectively. In the meta–analysis, there was no 
significant difference in survival between the groups (pooled HR 1.00, 95% CI 0.92–
1.09), as illustrated in Figure 21.  
Table 13. Characteristics of included studies. 
Source 
Country and 
Publication year 
Study period 
Total number of patients 
(pericardial/porcine) 
Mean follow-up 
time in years 
(pericardial/porcine) 
Andreas Austria 2015 2002-2008 458 (295/163) 6.0 (NA/NA) 
Chan Canada 2010 1990-2007 1659 (638/1021) 5.0 (3.9/5.6) 
Ganapathi USA 2015 1980-2013 2010 (1411/599) 5.4 (5.3/5.7) 
Glaser Sweden 2014 2002-2010 1219 (864/355) NA (4.2/6.9) 
Grunkemeier USA 2012 1976-2010 2825 (2356/469) NA (4.9/7.4) 
Hickey 
England and Wales 
2015 
2003-2013 38040 (24695/13345) 3.6 (median) 
Said USA 2012 1993-2007 2979 (1976/1003) 5.2 (5.2/5.1) 
  
 
Figure 21. Forest plot showing mortality after aortic valve replacement with bovine compared to porcine 
valve prostheses. 
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DISCUSSION 
Study I–II 
Survival and Aortic Valve Reoperation 
In Study I, we found no differences in mortality or rate of aortic valve reoperation after 
AVR between Perimount and Mosaic bioprostheses. Studies primarily analyzing 
mortality and the rate of reoperation after AVR using these two prostheses are scarce. 
However, our results are consistent with other studies which investigated long-term 
mortality and rate of reoperation after AVR with bovine versus porcine aortic valve 
prostheses.56,57 
Because of institutional directives, the two types of bioprostheses analyzed in our study 
were implanted mainly during different time periods, which might have influenced the 
results. However, pre-, peri-, and postoperative care were all similar throughout the 
entire study period, and therefore, it is unlikely that this would have affected the results. 
There is a current trend towards operating on older patients with more comorbidities 
than previously, and therefore, it could be hypothesized that the groups were not 
comparable. In that case, the patients in the Perimount group, who received the 
prostheses later, should have been older and sicker than the patients in the Mosaic 
group. However, this was not the case as the mean ages were 75.7 and 72.7 years in the 
Mosaic and Perimount groups, respectively. We adjusted for age and some other 
smaller between-group differences using multivariable regression methods. Because 
prosthetic valve selection was influenced by institutional directives rather than 
surgeon’s preference, the risk for confounding by indication (i.e., that patients in one 
group were different from patients in the other group), is less likely.  
In general, bioprostheses have satisfactory durability for at least 10 years, especially 
when implanted in older patients.58,61 It is therefore possible that the mean follow-up of 
4.9 years (maximum 11.1) was not long enough to detect between-group differences. 
However, six cases of early valvular dysfunction requiring reoperation have been 
reported with the Mosaic bioprosthesis,65,66 and therefore, even studies with shorter 
follow-up times are of interest.  
Hemodynamic Function 
In Study II, we found that patients who underwent AVR with Mosaic bioprostheses had 
acceptable long-term hemodynamic function. Some previous studies found that patients 
who underwent AVR with Mosaic bioprostheses had higher transvalvular gradients 
compared with patients who received other aortic bioprostheses.4,106 In our study, 
during late echocardiography, 34% of the study population had MPG 25 mmHg, 
corresponding to moderate or severe aortic stenosis. Increased transvalvular gradients 
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did not lead to higher mortality in our study population. It is possible that higher 
postoperative transvalvular gradients could have had other effects, such as lower 
functional status or even lower quality of life. Because we did not study these outcomes, 
this is only speculation that remains to be analyzed in future studies.  
Prosthesis–Patient Mismatch 
We found a higher prevalence of PPM in patients who received Mosaic than Perimount 
prostheses. Even if PPM is considered to be correlated with survival,31,32 this was not 
the case in our study population. However, it is possible that our study was 
underpowered to show such an association.  
Clinical Implications 
Study I was an observational study, and therefore, the aim was to analyze a possible 
association, not to prove causation. Study II may be used for hypothesis generation, as 
its primary outcome was entirely descriptive. Nevertheless, our results are consistent 
with those of several previous studies, which increase the likelihood of a causal effect, 
especially concerning patients’ similar survival with Perimount and Mosaic 
bioprostheses. Our results support both valve types as acceptable options for AVR. 
However, the increased postoperative transvalvular gradients and rate of PPM in the 
Mosaic group warrant further investigation, preferably with larger study cohorts and 
longer follow-up.  
Study III 
In Study III, we found that patients aged 50–69 years had better long-term survival after 
AVR with mechanical compared with biological valve prostheses. The optimal 
prosthesis type for middle-aged patients has been widely debated. The risk of aortic 
valve reoperation caused by bioprosthetic degeneration needs to be balanced against 
the increased risk of bleeding associated with mechanical valves and the necessary 
warfarin treatment. The few RCTs that have investigated whether biological or 
mechanical valves are better for middle-aged patients have been limited by non-
contemporaneous and small patient cohorts.107-109 Patient preference is of the utmost 
importance in the choice of valve type for each patient. Therefore, it will be difficult to 
perform an RCT in this patient group without substantial risk for selection bias. 
Therefore, large, real-world observational studies of this patient group are important. 
Previous observational studies have however reported contradictory results.70-72,110 
Chiang et al. performed an observational study of 4253 patients aged 50–69 years living 
in New York State who underwent isolated AVR with biological or mechanical valves.72 
They found no between-group differences in all-cause, long-term mortality or rate of 
stroke. The rate of aortic valve reoperation was higher in patients with biological valves, 
and the rate of major bleeding events was higher in patients with mechanical valves. 
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They concluded that bioprostheses might be a reasonable choice for patients as young 
as 50 years. In our study, which was performed in a similar way as the study by Chiang 
et al.72 but in the Swedish population, we found that patients with mechanical valves 
had better long-term survival than that of patients with biological valves. However, the 
two studies should be compared with caution because of their different study cohorts. 
The time within the therapeutic INR-range for patients treated with warfarin in Sweden 
has been shown to be high,111 which might improve the outcome of patients with 
mechanical valves. This is one possible explanation for the differences between our 
study and the study by Chiang et al. Goldstone et al.110 found that the survival benefit for 
patients with mechanical aortic valves compared with bioprostheses persisted until 55 
years of age. They also found a higher risk of major bleeding events and a lower risk of 
aortic valve reoperation with mechanical valves, which was consistent with our study 
and the one by Chiang et al.72 Interestingly, in the 45–54 years age group, they found a 
higher risk of stroke in patients with mechanical valves. Unfortunately, they did not 
analyze all-cause survival in patients aged 50–69 years. 
The increased use of bioprostheses has been justified partly by valve-in-valve TAVI as 
an alternative to surgical AVR in patients with degenerated bioprostheses, which may 
improve outcomes in patients with bioprostheses. However, the long-term durability of 
TAVI bioprostheses remains uncertain. Furthermore, in patients with certain anatomic 
variations (e.g., limited vascular access, bicuspid aortic valves, low take-off of the 
coronary arteries), and in patients having undergone surgical AVR with a small-sized 
prosthesis or valve-in-valve TAVI, it is not certain whether TAVI can be safely 
performed. Moreover, the newer generation On-X aortic mechanical valve allows for 
lower INR targets50 than conventional mechanical valves do. Further, self-monitoring 
and self-management of oral anticoagulation and telemedicine-guided dosing of oral 
anticoagulation have been shown to decrease thromboembolic events and allow for 
lower INR targets.112,113 This might decrease the risk of major bleeding events 
associated with higher INR targets and therefore improve outcomes in patients with 
mechanical valves. 
Clinical Implications 
The exact age cutoff for recommending biological or mechanical aortic valves remains 
controversial. No studies have found a survival benefit for middle-aged patients who 
received biological aortic valves, whereas several studies, including ours, found that 
patients with mechanical valves have better survival. These results are important 
because, during the last decade, bioprostheses have been increasingly used in all age 
groups,68,110 despite a lack of convincing scientific evidence to support this trend. Our 
study contributes to the existing knowledge about outcomes after AVR in patients aged 
50–69 years. This information can be used to guide prosthesis selection in middle-aged 
patients.  
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Study IV 
Survival 
In Study IV, we found a 28% higher long-term risk of death after AVR in patients with 
moderately reduced compared with normal kidney function. Several previous studies 
have found substantially worse survival after AVR in patients with ESRD.75,76 Even if 
moderately reduced kidney function affected as many as one-quarter of the patients 
who underwent AVR in our study, only a few studies have evaluated survival after AVR 
in these patients.84,114 Furthermore, most of these previous studies included patients 
with concomitant coronary artery bypass grafting, which might yield different results. 
Patients with coronary artery disease often have generalized atherosclerosis, which 
might affect the renal vasculature. Therefore, it is possible that these patients’ CKD has a 
different etiology than that of patients without coronary artery disease. Moreover, some 
of these studies used creatinine as an indicator of kidney function.75,115 Several factors 
influence the creatinine value, and therefore, eGFR is considered a better indicator of 
kidney function.82,83 
Aortic Valve Reoperation 
The risk of SVD in patients with moderately reduced kidney function is not known, but 
patients with ESRD are believed to have a higher risk of SVD than patients with normal 
kidney function have.80 Interestingly, we found a 62% lower risk of aortic valve 
reoperation in patients with moderately reduced compared with normal kidney 
function. It is possible that patients with moderately reduced kidney function were 
considered to have excessive operative risk and therefore did not undergo reoperation 
even if SVD had occurred.  
Major Bleeding Events 
Patients with renal failure have susceptibility to coagulation disorders that is believed 
to be caused by a complex interaction between platelet defects, the coagulation cascade, 
the fibrinolytic system, and platelet-vessel wall interaction defects.116 It is not known at 
what stage of renal failure these coagulation disorders start. Previous studies have 
found a higher risk of major bleeding events after AVR in patients with ESRD.80 In line 
with these results, we found a higher risk of bleeding events after AVR in patients with 
moderately reduced kidney function, but this difference did not reach statistical 
significance (HR 1.18, 95% CI 1.03–1.39, p=0.051).  
Survival in Patients with Moderately Reduced Kidney Function 
Patients with ESRD have a higher risk of both bleeding events and SVD after AVR, and 
therefore, it has been debated whether these patients benefit from biological or 
mechanical valve prostheses.117,118 We did not find a difference in survival between 
patients with moderately reduced kidney function who received biological versus 
  55 
mechanical valve prostheses. However, these results should be interpreted with caution 
because of the small numbers of patients and events. 
Clinical Implications 
Our results provide knowledge about outcomes after AVR in patients with moderately 
reduced kidney function. The results can be used for preoperative risk stratification and 
reference when designing future studies. Given the pessimistic prognosis after AVR in 
patients with moderately reduced kidney function, it is important with careful 
observation of these patients after surgery.  
Study V 
Prosthetic Valve Endocarditis 
In Study V, we found a yearly PVE rate of 0.57%. The incidence was highest during the 
first year after surgery and thereafter remained stable during follow-up. PVE was more 
common in patients who received bioprostheses compared to those who received 
mechanical valve prostheses. Previous studies of patients who underwent surgical AVR 
have reported a cumulative incidence of PVE of approximately 3% at 12 months.119,120 
These studies were however performed during the 1970s, which limits their 
generalizability to contemporary patients. A more recent study found an incidence rate 
of 0.7% per person-year after AVR.121 Regueiro et al.122 reported a yearly PVE rate of 
1.1% in patients after TAVI, and similar incidence rates have been reported after mitral 
valve replacement.123 
According to the European Society of Cardiology’s guidelines for the management of 
infective endocarditis39, there is no difference in PVE rates between patients who 
receive mechanical compared with biological valves. However, there are no references 
to support this statement. Brennan et al.124 performed a cohort study of 39 199 patients 
aged 65–80 years who underwent AVR in 605 hospital centers in the United States from 
1991 to 1999. Their primary endpoint was all-cause mortality, but they also reported a 
higher risk of PVE in patients with biological compared with mechanical valve 
prostheses (HR 1.60, 95% CI 1.31–1.94), which is in line with our results. They found a 
1.8% cumulative incidence rate of PVE 10 years after AVR. The cumulative incidence 
rate of PVE in our study was 0.47% at 10 years. Because Brennan et al.124 only included 
patients until 1999, and because their study population was older than ours, it is 
difficult to compare the results directly. A nationwide study of the Danish population 
performed by Østergaard et al. also found that patients with bioprostheses had higher 
risk of PVE than patients with mechanical valves after AVR.121 A small number of 
previous studies found no difference in PVE risk between biological and mechanical 
valves.70,108,125 However, these studies were limited by non-contemporary, small patient 
cohorts and small numbers of events.  
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Biological valve prostheses are expected to calcify gradually throughout a patient’s life. 
It is possible that the gradual degeneration of bioprostheses makes them susceptible to 
bacterial implantation and infection. Two previous studies found a higher incidence of 
PVE in patients with mechanical valves during the early follow-up period, and a higher 
risk of PVE in patients with biological valves during late follow-up,120,126 which 
strengthens this theory. However, we found a higher risk of PVE in patients with 
biological valve prostheses in both the early and late follow-up periods.  
Mortality after Prosthetic Valve Endocarditis 
The reported short-term mortality ranges from 6%–12% in patients with native valve 
infective endocarditis40,127,128 and from 12%–23% in patients with PVE.40,45,127,128 The 
previously reported short-term mortality after PVE is consistent with our findings, 
which showed a 30-day mortality after PVE of 12%–17% depending on treatment. In 
contrast to prior studies,129 we did not find a difference in mortality between patients 
who underwent surgery for PVE and those who were treated conservatively. However, 
these results should be interpreted with caution because of the small number of 
patients who underwent surgery for PVE in our study.  
Clinical Implications 
Our study provides a robust estimation of PVE incidence after AVR. The results extend 
the existing knowledge about possible complications after AVR with biological and 
mechanical valves. This study has direct clinical implications because it can facilitate 
diagnosis of PVE and prosthetic choice in selected patients. Furthermore, the numbers 
provided can function as reference values when designing future studies. 
Study VI 
In Study VI, we found no difference in long-term survival between patients who 
underwent AVR with bovine compared to porcine bioprostheses. Yap et al. performed a 
systematic review of articles comparing bovine and porcine aortic valve prostheses in 
2013.130 They found that bovine prostheses had advantageous hemodynamics 
compared with porcine prostheses, but they found no difference in survival between 
the two groups. However, none of the articles we included in our systematic review and 
meta-analysis were included in the study by Yap et al.130  
In line with previous studies,56,57 we found no difference in survival between patients 
who underwent AVR with bovine versus porcine bioprostheses. Initially, we also 
wanted to compare the rate of aortic valve reoperations and the prevalence of PPM. 
However, the small number of eligible articles and difficulties finding comparable 
articles required that we limit our study to survival. One of the included articles in our 
study found slightly better survival in patients with porcine prostheses, whereas the 
remaining six articles found no statistically significant between-group differences in 
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survival. One study that did not report HR, and therefore was not included in our study, 
reported a survival benefit for patients with bovine prostheses.4 Our study does not 
prove causality, and thus, the question of whether survival is the same after AVR with 
bovine and porcine prostheses cannot be entirely answered by our study. However, 
when summarizing the available evidence, the superior hemodynamics, higher degree 
of left ventricular mass regression, and the lower frequency of PPM previously reported 
with bovine prostheses4,131 do not seem to translate into better survival. However, 
whether bovine prostheses lead to higher rates of aortic valve reoperations, lower 
functional status, or lower quality of life remains unknown.  
Clinical Implications 
This study contributes to the existing knowledge about different types of aortic valve 
bioprostheses by summarizing the scientific evidence in the field. The results can be 
used as quality indicators, and they suggest that both bovine and porcine bioprostheses 
are good alternatives for AVR.  
Strengths and Limitations 
Methodological Considerations 
All studies were observational studies except Study VI, which was a systematic review 
and meta-analysis. However, even Study VI has the disadvantages that come with 
observational studies because all the included studies in the systematic review and 
meta-analysis were themselves observational. First, observational studies can prove 
only association rather than causality. Second, group allocation is not random in 
observational studies, and therefore, it is likely that the groups are different at baseline. 
In Study I–V, we used multivariable regression models to adjust for differences in 
baseline characteristics between the groups. In Study III–IV, we also used propensity 
score methods to further account for these differences. Nevertheless, in observational 
studies, there is always a risk of residual confounding (i.e., that some factors were 
unknown or unmeasured and therefore could not be adjusted for).  
Another type of inevitable error that can be present in all study designs is random error. 
Random error reflects the role of chance. The smaller the study size, the larger the risk 
of random error. In Study III–V, the study populations were large, and there were many 
events, which decreases the risk of random errors. However, large sample sizes are 
associated with smaller detectable differences, and therefore, it is important to consider 
clinically significant differences rather than statistically significant differences.  
Study I–V were population-based, meaning that all eligible patients that lived in a 
specific region were included in the study. In population-based cohort studies, the risk 
of selection bias (i.e., that the people included in the study are different from those not 
included in the study) is smaller than if only a sample of the population is included in 
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the study. Furthermore, including all eligible people in one region increases the study’s 
external validity (i.e., its generalizability). The larger and more representative the 
region is, the higher the external validity is. Study III–V were also nationwide. It is 
therefore likely that the results of our studies can be generalized to both Sweden and 
other countries with similar healthcare standards to those of Sweden.  
In Study I–II, we used medical records and national registers to obtain information 
about the study population, and Study III–V were entirely register-based. The Swedish 
national registers have repeatedly been shown to have high quality, which is a 
particular strength of our studies. Other strengths include complete follow-up for death 
(the data availability of which is 100% thanks to the completeness of the national 
registers) and a large number of patients. 
Study I–II 
These studies were single-center studies, which might decrease their external validity. 
However, differences in pre-, peri-, and postoperative care were minimized because all 
patients were operated in the same center. Data regarding patient characteristics and 
outcomes were obtained manually from medical records. Consequently, existing data 
could have been missed, and data that were not available from medical records were 
not included.  
In Study II, long-term hemodynamic data were only available for 161 (45%) patients of 
the total cohort of 355 patients. Of these, approximately two-thirds underwent 
echocardiography as part of their clinical care. It is possible that patients with 
symptoms, and consequently affected hemodynamics, were more likely to undergo late 
echocardiography than patients without symptoms were. This could have biased the 
results towards higher postoperative gradients. Furthermore, the echocardiography 
performed as part of the patients´ clinical care was performed by different people, not 
according to a predefined study protocol. However, most echocardiography in Sweden 
is performed by clinical physiologists in accordance with a standardized protocol, which 
decreases the risk of information bias (i.e., a systematic error caused by erroneous 
information collected about or from the study subjects132). 
Study III 
We did not have information about the different types of biological and mechanical 
prostheses used in this study. It is possible that patients receiving certain types of 
prostheses have better outcomes than patients receiving other types of prostheses. 
Furthermore, we did not have information about implanted valve size or the prevalence 
of PPM.  
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Study IV 
Because kidney function constituted the exposure groups in this study, patients with 
missing creatinine were excluded. This may have introduced selection bias, which in 
turn might limit generalizability. To account for this possibility, we analyzed the 
prognosis of patients with missing creatinine and found similar results to those of 
patients with creatinine values present. This indicates that the difference between 
included and excluded patients was not important. We used the most recent 
preoperative creatinine value to calculate each patient’s eGFR. However, the creatinine 
value might differ in the same individual depending on factors such as hydration status, 
protein intake, and exercise level. Therefore, some patients might have erroneously 
ended up in the incorrect kidney function groups. Furthermore, we did not have 
information about implanted valve size, cardiopulmonary bypass time, cause of CKD, or 
degree of frailty, which might have been a cause of residual confounding.  
Study V 
The criteria for diagnosing a patient with endocarditis might differ between hospitals 
and treating physicians, which might have introduced information bias in this study. 
Also, it is often difficult to diagnose endocarditis. Not all patients have positive blood 
cultures (e.g., those with recent use of antibiotics, immunosuppressed patients, and 
patients with bacteria that require different culture techniques), and older or frail 
patients may be underdiagnosed. Consequently, we might have underestimated the 
incidence of PVE. However, it is likely that the incidence of PVE was equally 
underestimated in patients with biological and mechanical valves, and therefore, the 
relative risk was probably not affected. Furthermore, we could not distinguish between 
infection affecting the aortic valve prostheses and other heart valves or cardiac 
implantable electronic devices. This might have led to an overestimation of the 
incidence of PVE. We did not have information about patient frailty, dental hygiene, 
antibiotic use, echocardiographic or other imaging data, or frequency of infections such 
as dental infections, pneumonia, mediastinitis, or urinary tract infections before, at the 
time of, or after surgery. For example, it is possible that patients with a higher degree of 
frailty and worse dental hygiene may have been more likely to receive bioprostheses 
and therefore had a higher risk of PVE. Furthermore, for patients with diagnosed PVE, 
the time from symptoms to hospital admission and surgery, if performed, is not known. 
A time delay between disease onset and treatment might have influenced mortality 
after PVE negatively. However, the data come from real-world experience, which 
increases generalizability.  
Study VI 
Even though systematic reviews and meta-analyses are often considered to have the 
potential to provide the highest level of evidence, the quality of the systematic review 
always depends on the quality of the included studies. In our study, all of the included 
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studies were observational, with the inherited limitation of possible residual 
confounding. Furthermore, because prosthetic choice was not randomly allocated, it is 
possible that the operating surgeon chose a certain prosthesis type for certain patients, 
which could lead to differences between the groups at baseline. For example, it is 
possible that a bovine prosthesis was chosen for younger and healthier patients or for 
patients with a smaller aortic annulus if the surgeon believed the bovine prostheses to 
have better hemodynamics and a lower degree of PPM. In that case, the mortality of 
patients who received bovine prostheses might have been underestimated. Further, we 
found moderate heterogeneity in our study, which might reflect important differences 
between the studies. For example, different types and brands of bovine and porcine 
prostheses were used in the different studies. It is possible that that the true effect 
differs between different types of prostheses, and therefore, this distinction might have 
influenced the results. As with Study I–II, it is possible that the follow-up was not long 
enough to detect a survival difference between the groups.  
Even though we performed a thorough literature search, it is not certain that we found 
all eligible articles. Further, it is possible that mainly studies with positive results have 
been published, which could lead to an under- or overestimation of the effect measure. 
The largest advantage of this study is that it is, to the best of my knowledge, the first 
complete systematic review and meta-analysis performed on this topic. Other strengths 
include the large number of patients and the strict inclusion criteria, which make the 
articles more comparable. 
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Future Perspectives 
The primary outcome in all studies except Study II and V was all-cause mortality. This is 
an important endpoint, but other factors, such as functional status, quality of life, and 
repeat hospitalizations might be equally important to individual patients. More 
information about these factors would be helpful when choosing the optimal valve 
prosthesis for each patient, and studies evaluating outcomes other than survival are 
needed.  
To provide causality rather than associations, large RCTs are in demand. Because 
patient preference is of the utmost importance when choosing valve type, random 
allocation of biological and mechanical valves will be difficult. However, it might be 
feasible to conduct an RCT comparing bovine and porcine aortic valve prostheses, 
which could be facilitated with register-based randomization. The information provided 
from such a trial could also be useful in the era of TAVI, in which both bovine and 
porcine prostheses are used. Furthermore, future studies with longer follow-up, both 
for bovine versus porcine and biological versus mechanical prostheses, would provide 
useful information.  
Moderately reduced kidney function is present in one-quarter of patients who undergo 
AVR. The majority of studies that evaluate outcomes, prosthesis choice, and prognosis 
after AVR in patients with CKD are performed in patients with ESRD. More studies 
evaluating operation-related outcomes in patients with moderately reduced kidney 
function instead of ESRD are needed. It would also be interesting to investigate at what 
GFR level alterations in the coagulation system occur.  
We found a higher incidence of PVE in patients with bioprostheses than mechanical 
valves. However, the mechanism behind these results is not clear, and it is not certain 
that the association found resulted from a causal relationship. More studies evaluating 
this possible association in different patient cohorts are needed. 
The continued development of mechanical valves with less thrombogenic properties 
and biological valves that are less prone to SVD will greatly benefit all patients who 
undergo AVR. The dream scenario would be to find a perfect valve prosthesis that does 
not require anticoagulation treatment AND has excellent durability. 
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CONCLUSIONS 
 
Study I Long-term, all-cause mortality after AVR was similar in patients with 
Perimount and Mosaic bioprostheses. Both Perimount and Mosaic 
bioprostheses are acceptable valve choices for AVR.  
Study II Mosaic bioprostheses had acceptable hemodynamic function after AVR. A 
substantial proportion of the patients who underwent AVR with a Mosaic 
bioprosthesis had increased postoperative gradients or moderate to severe 
PPM. However, this was not associated with increased mortality in our 
cohort.  
Study III In patients aged 50–69 years, survival after AVR was better for those who 
received mechanical valve than biological prostheses. The increased use of 
bioprostheses in this age group does not have sufficient scientific support.  
Study IV Mortality after AVR was higher in patients with moderately reduced 
kidney function than in those with normal kidney function. Patients with 
reduced kidney function warrant careful observation after AVR. 
Study V After AVR, the yearly rate of PVE was 0.57%. We found a higher relative 
risk for PVE in patients with biological than mechanical valve prostheses in 
both the early and late postoperative periods. These results can facilitate 
diagnosis of PVE and prosthetic choice in selected patients. 
Study VI Long-term, all-cause mortality after surgical AVR was similar in patients 
with bovine and porcine bioprostheses. Both bovine and porcine 
bioprostheses are acceptable valve choices for AVR. 
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